documents incorporated reference specified portions registrants proxy statement filed commission pursuant regulation connection registrants annual meeting stockholders held may incorporated reference part iii report based closing price per share june excludes shares registrants common stock held executive officers directors stockholders whose ownership exceeds registrants common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registrantgilead sciences inc annual report table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item mine safety disclosures part ii item market registrants common equity related stockholder matters issuer purchases equity securities item reserved item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information item c disclosure regarding foreign jurisdictions prevent inspections part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules item summary signatures rights various trademarks trade names used business including following gilead gilead sciences kite ambisome atripla biktarvy cayston complera descovy descovy prep emtriva epclusa eviplera genvoya harvoni hepcludex hepsera jyseleca letairis odefsey ranexa sovaldi stribild sunlenca tecartus trodelvy truvada truvada prep tybost veklury vemlidy viread vosevi yescarta zydelig report also refers trademarks service marks trade names companies property respective ownersthis annual report including part ii item managements discussion analysis financial condition results operations contains forwardlooking statements regarding future events future results subject safe harbors created securities act amended securities act securities exchange act amended exchange act words expect anticipate target goal project hope intend plan believe seek estimate continue may could might forecast variations words similar expressions intended identify forwardlooking statements addition statements statements historical fact forwardlooking statements including statements regarding overall trends operating cost revenue trends liquidity capital needs plans expectations respect products product candidates corporate strategy business operations financial projections use capital collaboration licensing arrangements patent protection estimated loss exclusivity products product candidates ongoing litigation investigation matters statements regarding anticipated future impact business coronavirus disease covid related public health measures statements expectations beliefs future plans strategies anticipated events trends similar expressions based forwardlooking statements current expectations future events statements guarantees future performance involve risks uncertainties assumptions difficult predict actual results may differ materially suggested forward looking statements various reasons including identified part item risk factors annual report given risks uncertainties cautioned place undue reliance forwardlooking statements forwardlooking statements included report made date hereof unless otherwise specified except required federal securities laws rules regulations us securities exchange commission sec undertake specifically decline obligation update statements publicly announce results revisions forwardlooking statements distribution report whether result new information future events changes assumptions otherwise evaluating business carefully consider risks described part item risk factors annual report risks contained herein could materially adversely affect business results operations financial condition part item business gilead sciences inc gilead us biopharmaceutical company pursued achieved breakthroughs medicine three decades goal creating healthier world people committed advancing innovative medicines prevent treat lifethreatening diseases including hiv viral hepatitis cancer operate countries worldwide headquarters foster city california business products transformed care people around world discovering developing delivering innovative medicines address unmet medical needs virology oncology therapeutic areas innovative medicines represent advancements offering firstinclass therapies greater efficacy enhanced modes delivery convenient treatment prevention regimens improved resistance profiles reduced side effects primary revenuegenerating products approved indications us follows hiv biktarvy oral formulation dosed day treatment hiv infection certain patients biktarvy singletablet regimen fixeddose combination antiretroviral medications bictegravir emtricitabine ftc tenofovir alafenamide taf genvoya oral formulation dosed day treatment hiv infection certain patients genvoya singletablet regimen fixeddose combination antiretroviral medications elvitegravir cobicistat ftc taf descovy oral formulation indicated combination antiretroviral agents treatment hiv infection certain patients descovy fixeddose combination antiretroviral medications ftc taf descovy also approved us food drug administration fda pre exposure prophylaxis prep indication reduce risk sexually acquired hiv infection certain atrisk patients odefsey oral formulation dosed day treatment hiv infection certain patients odefsey singletablet regimen fixeddose combination antiretroviral medications ftc taf rilpivirine marketed janssen sciences ireland unlimited company one janssen pharmaceutical companies johnson johnson janssen compleraeviplera oral formulation dosed day treatment hiv infection certain patients product marketed us complera europe eviplera singletablet regimen fixeddose combination antiretroviral medications tenofovir disoproxil fumarate tdf ftc janssens rilpivirine hydrochloride truvada oral formulation indicated combination antiretroviral agents treatment hiv infection certain patients truvada fixeddose combination antiretroviral medications tdf ftc truvada also approved fda prep indication reduce risk sexually acquired hiv infection certain atrisk patients stribild oral formulation dosed day treatment hiv infection certain patients stribild singletablet regimen fixeddose combination antiretroviral medications elvitegravir cobicistat tdf ftc covid veklury remdesivir injection intravenous use nucleotide analog rna polymerase inhibitor indicated treatment coronavirus disease covid certain adults pediatric patients days age older weighing least kg hospitalized ii hospitalized mildtomoderate covid high risk progression severe covid including hospitalization death viral hepatitis epclusa oral formulation oncedaily singletablet regimen sofosbuvir velpatasvir treatment chronic hepatitis c virus hcv infection adults pediatric patients years age older genotype without cirrhosis compensated cirrhosis ii decompensated cirrhosis use combination ribavirin addition authorized generic version epclusa distributed separate subsidiary asegua therapeutics llc vemlidy oral formulation taf dosed day treatment chronic hepatitis b virus hbv infection adults pediatric patients years age older compensated liver disease harvoni oral formulation oncedaily singletablet regimen ledipasvir sofosbuvir treatment chronic hcv infection adults pediatric patients years age older genotype without cirrhosis compensated cirrhosis ii genotype decompensated cirrhosis combination ribavirin iii genotype liver transplant recipients without cirrhosis compensated cirrhosis combination ribavirin addition authorized generic version harvoni distributed separate subsidiary asegua therapeutics llc viread oral formulation tdf dosed day treatment chronic hbv infection adults pediatric patients years age older weighing least kg oncology yescarta axicabtagene ciloleucel suspension intravenous infusion chimeric antigen receptor car tcell therapy treatment adult patients large bcell lymphoma lbcl refractory firstline chemoimmunotherapy relapses within months firstline chemoimmunotherapy ii adult patients relapsed refractory lbcl two lines systemic therapy including diffuse lbcl dlbcl otherwise specified primary mediastinal lbcl highgrade bcell lymphoma dlbcl arising follicular lymphoma fl iii adult patients relapsed refractory fl two lines systemic therapy trodelvy sacituzumab govitecanhziy injection intravenous use trop directed antibody topoisomerase inhibitor conjugate indicated treatment adult patients unresectable locally advanced metastatic triplenegative breast cancer tnbc received two prior systemic therapies least one metastatic disease ii unresectable locally advanced metastatic hormone receptorpositive human epidermal growth factor receptor negative hrher breast cancer received endocrinebased therapy least two additional systemic therapies metastatic setting iii locally advanced metastatic urothelial cancer uc previously received platinumcontaining chemotherapy either programmed death receptor pd programmed deathligand pdl inhibitor tecartus brexucabtagene autoleucel suspension intravenous infusion car tcell therapy treatment adult patients relapsed refractory mantle cell lymphoma mcl ii relapsed refractory bcell precursor acute lymphoblastic leukemia indication approved accelerated approval fda continued approval indication may contingent upon verification description clinical benefit confirmatory trials indication received fda approval february ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treatment serious invasive fungal infections caused various fungal species adults letairis ambrisentan oral formulation endothelin receptor antagonist treatment pulmonary arterial hypertension pah group improve exercise capacity delay clinical worsening ii combination tadalafil reduce risks disease progression hospitalization worsening pah improve exercise ability disaggregated revenue amounts contributed products listed well total product sales include approved products see note revenues notes consolidated financial statements included part ii item annual report december received fda approval sunlenca lenacapavir hiv capsid inhibitor tablet form oral use injection subcutaneous use sunlenca combination antiretrovirals approved twiceyearly treatment option hiv infection heavily treatment experienced adults multidrug resistant hiv infection revenue share revenues also generate revenues activities including revenue share combination products royalties outbound licenses intellectual property payments received collaborations thirdparty partners example pursuant collaboration janssen receive revenue share cobicistat ftc taf components symtuza darunavircobicistatftctaf fixeddose combination product commercialized janssen include revenue share symtuza product sales description collaborations janssen partners see note collaborations arrangements notes consolidated financial statements included part ii item annual report commercialization distribution us international commercial sales operations marketing subsidiaries countries products marketed commercial teams andor conjunction thirdparty distributors corporate partners commercial teams promote products direct field contact physicians hospitals clinics healthcare providers generally grant thirdparty distributors exclusive right promote product territory specified period time agreements distributors provide collaborative efforts distributor gilead obtaining maintaining regulatory approval product specified territory sell distribute products us exclusively wholesale channel year ended december approximately product sales us approximately total worldwide revenues three large wholesalers amerisourcebergen corporation cardinal health inc mckesson corporation sell distribute products europe countries outside us product approved either commercial teams thirdparty distributors corporate partners competition operate highly competitive environment products compete commercially available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance ease use price insurance reimbursement coverage distribution marketing also face significant competition third parties pursue development products technologies may competitive existing products research programs third parties include large pharmaceutical biotechnology companies specialized pharmaceutical firms acting either independently together companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs addition products mature pricing pressures private insurers government payers often result reduction net product prices new branded generic products introduced major markets ability maintain pricing market share may affected research development research development rd mission discover develop transformational therapies areas high unmet medical need product development efforts focused primarily viral diseases oncology inflammatory diseases team research scientists engaged discovery development new molecules technologies hope lead approval innovative medicines therapies transform care people around world intend continue committing significant resources internal rd opportunities external business development activity drive innovation growth business development product candidates investigational therapies pipeline subject various risks uncertainties risks uncertainties include challenges clinical trial protocol design ability enroll patients clinical trials possibility unfavorable inadequate trial results support development product candidates including failure meet trials primary endpoint safety issues arising clinical trials need modify delay clinical trials perform additional trials result may unable successfully complete clinical trials anticipated timelines based trial results possible fda regulatory authorities approve product candidates market approvals include significant limitations products use may make strategic decision discontinue development product candidates example believe commercialization difficult relative opportunities pipeline therefore product candidates may never successfully commercialized may unable recoup significant rd clinical trial expenses incurred expect expend significant time resources rd activities without assurance recoup investments efforts commercially successful drug development inherently risky many product candidates investigational therapies fail development process continued invest advance rd pipeline across therapeutic areas summary product candidates phase registrational phase clinical trials pending marketing authorization review fda european medicines agency ema product candidates viral diseases product candidates description regulatory filings bulevirtide biologics license application bla filed fda bulevirtide treatment chronic hepatitis delta virus hdv infection granted orphan drug breakthrough therapy designations fda indication approval pending resolution certain manufacturing delivery concerns cited complete response letter issued fda october europe hepcludex bulevirtide granted conditional marketing authorization european commission ec priority medicines prime scheme eligibility ema first approved treatment adults chronic hdv infection compensated liver disease phase lenacapavir lenacapavir evaluated hiv prep indication gs gs novel oral covid nucleoside evaluated treatment covid infection product candidates oncology product candidates description regulatory filings sacituzumab govitecanhziy type ii variation marketing authorization application filed ema sacituzumab govitecanhziy trop directed antibody topoisomerase inhibitor conjugate treatment adult patients unresectable metastatic hrher breast cancer received endocrinebased therapy least two additional systemic therapies metastatic setting indication received fda approval february phase axicabtagene ciloleucel axicabtagene ciloleucel car tcell therapy evaluated secondline later treatment highrisk follicular lymphoma sacituzumab govitecanhziy sacituzumab govitecanhziy evaluated second thirdline treatment nonsmall cell lung cancer nsclc ii firstline treatment pdl negative metastatic triplenegative breast cancer tnbc iii secondline treatment metastatic urothelial cancer collaboration merck sharp dohme llc merck sacituzumab govitecanhziy evaluated combination mercks pembrolizumab firstline treatment pdl positive metastatic tnbc ii firstline treatment nsclc sacituzumab govitecanhziy also evaluated combination pembrolizumab treatment adjuvant tnbc magrolimab magrolimab anticd monoclonal antibody evaluated combination azacitidine firstline treatment higher risk myelodysplastic syndrome mds granted breakthrough therapy designation fda prime scheme eligibility indication magrolimab also evaluated combination azacitidine firstline treatment tpm acute myeloid leukemia aml magrolimab also evaluated combination venetoclax azacitidine firstline treatment unfit aml domvanalimab zimberelimab collaboration arcus biosciences inc arcus combination zimberelimab antipd monoclonal antibody domvanalimab fcsilent antitigit antibody evaluated firstline treatment nsclc collaboration arcus combination zimberelimab domvanalimab chemotherapy also evaluated firstline treatment nsclc ii firstline treatment upper gastrointestinal tract cancer collaboration arcus astrazeneca combination domvanalimab durvalumab evaluated treatment stage nsclc registrational phase brexucabtagene autoleucel brexucabtagene autoleucel car tcell therapy evaluated treatment pediatric acute lymphoblastic leukemia additional information regarding collaborations merck arcus see note collaborations arrangements notes consolidated financial statements included part ii item annual report also received regulatory approvals authorizations fda ec new products expanded indications products including product regulatory approval authorization sunlenca fda ec approved sunlenca firstinclass longacting hiv capsid inhibitor treatment hiv infection combination antiretrovirals adults multidrug resistant hiv heavily treatmentexperienced sunlenca new twiceyearly treatment option adults hiv infection adequately controlled current treatment regimen yescarta fda approved yescarta treatment adult patients lbcl refractory firstline chemoimmunotherapy relapses within months firstline chemoimmunotherapy yescarta first fdaapproved car tcell therapy initial treatment relapsed refractory lbcl ec approved yescarta treatment adult patients dlbcl highgrade bcell lymphoma relapse within months completion refractory firstline chemoimmunotherapy yescarta first car tcell therapy approved patients europe respond firstline treatment dlbcl highgrade bcell lymphoma ec also approved yescarta treatment adult patients relapsed refractory fl three lines systemic therapy tecartus ec approved tecartus treatment adult patients years age relapsed refractory bcell precursor veklury fda approved expanded use veklury treatment nonhospitalized patients high risk progression severe covid including hospitalization death fda also expanded approval veklury include pediatric patients days age older weighing least kg biktarvy ec approved lowdose tablet dosage form biktarvy extension indication biktarvy treat hiv infection virologically suppressed children least two years age weigh least kg vemlidy fda approved expanded use vemlidy treatment chronic hbv infection pediatric patients years age older compensated liver disease trodelvy fda approved trodelvy treatment unresectable locally advanced metastatic hrher breast cancer received endocrinebased therapy least two additional systemic therapies metastatic setting indication received fda approval february addition seek enhance commercial portfolio clinical pipeline across multiple therapeutic areas acquisitions inlicensing strategic collaborations announced multiple strategic collaborations including research collaboration dragonfly therapeutics inc develop natural killer cell engagerbased immunotherapies oncology inflammation ii global strategic collaboration arcellx inc codevelop cocommercialize arcellxs lead latestage product candidate cartddbcma treatment relapsed refractory multiple myeloma iii oncology collaboration macrogenics inc develop bispecific antibodies including gileads exclusive option license mgd potential treatment certain blood cancers also announced acquisitions mirobio private ukbased biotech company focused restoring immune balance agonists targeting immune inhibitory receptors ii tmunity therapeutics clinicalstage private biotech company focused nextgeneration car tcell therapies technologies iii remaining rights gs anticcr antibody development potential treatment solid tumors jounce therapeutics inc strategic business development activity reflects commitment focus transformative science build sustainable diverse portfolio position near medium longterm growth business patents proprietary rights us european patent expiration number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows estimated expiration dates including patent term extensions supplementary protection certificates andor pediatric exclusivity granted us european union eu primary typically compound patents key product candidates described product candidates fixeddose combinations singletablet regimens estimated patent expiration date provided corresponds latest expiring compound patent one active ingredients singletablet regimen key product candidates patent expiration us eu viral diseases lenacapavir bulevirtide inflammatory diseases cilofexor filgotinib oncology axicabtagene ciloleucel brexucabtagene autoleucel sacituzumab govitecanhziy magrolimab zimberelimab domvanalimab listed expiration dates include potential additional exclusivity eg patent term extensions supplementary protection certificates pediatric exclusivity yet granted composition matter patent expired eu eu us patent applications pending relating proprietary manufacturing processes kite gilead company kite regulatory exclusivity us expires collaboration arcus dates parentheses reflect estimated expiration date patents may issue currently pending applications following table shows actual estimated expiration dates including patent term extensions supplementary protection certificates andor pediatric exclusivity granted us eu primary typically compound patents principal products products fixeddose combinations singletablet regimens estimated patent expiration dates provided correspond latest expiring compound patent one active ingredients singletablet regimen products patent expiration us eu descovy vemlidy compleraeviplera zydelig odefsey yescarta stribild genvoya harvoni epclusa biktarvy vosevi veklury tecartus trodelvy jyseleca hepcludex sunlenca listed expiration dates include potential additional exclusivity eg patent term extensions supplementary protection certificates pediatric exclusivity yet granted applicable settlement license agreements generic manufacturers relating patents protect principal products noted nature timing loss exclusivity products depends multitude factors loss exclusivity may earlier certain circumstances information see item risk factors success depends significant degree ability obtain defend patents intellectual property rights domestically internationally operate without infringing upon patents proprietary rights third parties september gilead five generic manufacturers lupin ltd apotex inc macleods pharma ltd hetero labs ltd cipla ltd reached agreements settle us patent litigation concerning patents protect taf descovy vemlidy odefsey products composition matter patent expired eu eu us patent applications pending relating proprietary manufacturing processes kite gilead mylan pharmaceuticals reached agreement settle patent litigation concerning patents protect cobicistat stribild genvoya products regulatory exclusivity us expires patent protection certain challenges patents proprietary rights important business properly drafted enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection us internationally file additional patent applications appropriate cover improvements compounds products technology patents covering certain active pharmaceutical ingredients api products held third parties acquired exclusive rights patents agreements parties may obtain patents certain products many years marketing approval obtained result commercial value patent may limited patent term based date patent application filed may prior regulatory approval commercial sale related product however may able apply patent term extensions supplementary protection certificates countries example extensions patents supplementary protection certificates many products granted us number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain countries also important infringe valid patents third parties infringe valid patents third parties reputation may harmed may required pay significant monetary damages may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware patents patent applications owned parties parties may claim cover use products research activities patent applications confidential period time filing may know competitors filed applications technology covered pending applications first invent first file application directed toward technology subject patent applications competitors may filed patent applications received patents proprietary rights block compete products addition competitors file patent applications covering technology may participate litigation postgrant proceedings us patent trademark office proceedings determine right patent validity patent granted litigation proceedings unpredictable expensive could divert management attention operations even ultimately successful may adversely impacted patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection filing patent applications factintensive complex process may file patent applications ultimately result patents patents provide adequate protection related product future litigation proceedings regarding enforcement validity existing patents future patents could result invalidation patents substantially reduce protection time time certain individuals entities may challenge patents pending patent applications patent applications filed collaborative partners may able prevent third parties developing compounds products closely related developed developing addition certain countries provide effective enforcement patents thirdparty manufacturers may able sell generic versions products countries may face criticism result legitimate use patent systems protect investments new useful innovations medicine incentives exclusivities relating products product candidates may change future aware several countries considering changes support sharing make use new inventions could impact current patent systems protections innovation changes could also impact voluntary licensing patent programs establish products support access medicines description significant pending legal proceedings see note commitments contingencies notes consolidated financial statements included part ii item annual report see also item risk factors success depends significant degree ability obtain defend patents intellectual property rights domestically internationally operate without infringing upon patents proprietary rights third parties trade secrets also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets internal knowhow technological innovation otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partners cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions trade secrets confidential information become known independently discovered competitors enter disputes ownership inventions business results operations could adversely affected manufacturing raw materials products manufactured either facilities thirdparty contract manufacturers depend third parties perform manufacturing activities majority api drug products products including hiv hcv products use multiple thirdparty contract manufacturers primary backup suppliers manufacturing sites cell therapy products established clinical commercial manufacturing facilities cell processing activities future products continue develop additional manufacturing capabilities establish additional thirdparty suppliers manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities product approved commercial sale manufacturing facilities lease manufacturing facilities manufacture distribute certain products api clinical andor commercial uses end facilities include foster city california conduct process chemistry research analytical method development formulation device development activities manufacture api drug product clinical trials san dimas la verne california manufacture ambisome also package label majority commercial products distribution americas pacific rim oceanside california utilize facility commercial retroviral vector manufacturing clinical manufacturing process development biologics candidates el segundo california utilize facility clinical commercial manufacturing processing cell therapy products frederick maryland utilize facility clinical commercial manufacturing processing cell therapy products cork dublin ireland utilize cork facility commercial manufacturing packaging labeling products also perform quality control testing labeling packaging final release many products cork facility distributed eu international markets facility dublin edmonton canada conduct process chemistry research scaleup activities clinical development candidates manufacture api investigational commercial products conduct chemical development activities improve existing commercial manufacturing processes hoofddorp netherlands utilize facility commercial manufacturing processing cell therapy products thirdparty manufacturers believe technology use manufacture products proprietary products manufactured thirdparty contract manufacturers disclosed necessary aspects technology enable manufacture products us agreements thirdparty manufacturers intended restrict using revealing technology certain thirdparty manufacturers comply restrictions information thirdparty manufacturers see item risk factors may face manufacturing difficulties delays interruptions including thirdparty manufacturers corporate partners regulation manufacturing process manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities observe complying regulations thirdparty manufacturers corporate partners subject current good manufacturing practices gmp extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda ema similar regulations effect jurisdictions manufacturing operations subject routine inspections regulatory agencies cell therapy products required fda comply risk evaluation mitigation strategy program includes educating certifying medical personnel regarding therapy procedures potential side effect profile therapy potential adverse side effects related cytokine release syndrome neurologic toxicities additionally required maintain complex chain identity custody respect patient material material moves manufacturing facilities manufacturing process back patient access raw materials need access certain raw materials conduct clinical trials manufacture products raw materials generally available multiple sources purchased worldwide normally available quantities adequate meet needs business attempt manage risks associated supply chain inventory management relationship management evaluation alternative sources feasible information see item risk factors may able obtain materials supplies necessary conduct clinical trials manufacture sell products could limit ability generate revenues human capital gileads success depends work dedicated employees embrace shared sense purpose culture excellence human capital objective make gilead employer choice best talent industry gileads key priorities human capital management include inclusion diversity health safety total rewards employee development engagement compensation talent committee board directors oversees overall human capital management inclusion diversity inclusion gilead core value believe building inclusive diverse workforce critical enabling gileads mission global inclusion diversity council responsible governance matters tracking progress goals promoting culture inclusion global inclusion diversity council chaired chairman chief executive officer includes members leadership team introduced advancing black leadership strategy multiyear initiative outlines commitments create internal external pipelines diverse talent build awareness capabilities accountability among people managers part strategy set clear targets representation within overall workforce executive populations including goals increase percentage female black hispanic employees welldefined annual targets gilead also implemented multiple programs train managers inclusion diversity topics created strategies initiatives focused attracting developing retaining diverse talent driving inclusive culture workplace organizational leaders required regularly review starting addition employee resource groups ergs support diverse employees aim raise awareness different cultures within workplace cultivate diversity business strength support gileads talent acquisition strategy source attract recruit diverse candidates executive sponsors leaders ergs contribute advancement inclusion diversity commitments service global inclusion diversity council believe gileads inclusive diverse workforce foundation innovation productivity gileads commitment equal employment opportunity furthers efforts cultivate celebrate equitable culture belonging december gilead approximately employees gileads global workforce approximately female additionally women represented gileads leadership defined vice president level us based employees voluntary selfidentification workforce white asian hispanic black health safety gilead committed providing workplace employees promotes health safety wellness productivity workplace safety training security program together various compliance protocols support commitment routinely train educate employees workplace safety security response covid pandemic implemented job site enhancements risk protocols including health screenings covid testing vaccine requirements reconfiguration work common spaces allow physical distancing effort support safe occupancy sites gilead also maintains robust contact tracing notification process employee reports covid infection total rewards gileads compensation benefits programs designed help attract develop retain industrys talented workforce total rewards program varies country includes competitive base salary incentive compensation stock awards employee stock purchase plan k savings plan company match vests immediately health welfare valuable benefits flexible work arrangements flexible spending accounts paid time family leave family care resources fertility adoption surrogacy assistance student loan repayment tuition assistance employee assistance programs global wellbeing reimbursement among many others year reassess total rewards package confirm whether offers benefits incentives align total reward philosophy payforperformance company committed addressing pay equity employee salaries informed marketbased ranges assessed annually performance career development reviews policy compensation decisions made without regard personal characteristics gender race color national ethnic origin age disability sexual orientation gender identity expression genetic information religion veteran status also conduct annual pay equity review employee compensation effort strive make pay practices gender raceneutral employee development engagement employee development engagement maximizes potential performance member workforce critical achieving business goals gilead offers number internal external professional management leadership development training programs help employees develop technical crossfunctional leadership skills tools grow careers addition employees receive reimbursement tuition expenses incurred pursuing undergraduate graduate certificate courses accredited college university strive employer choice industry listening strategy gathers input employees shape engagement strategies programs measure progress addition ongoing internal external data collection benchmarking conducted comprehensive reviews employee experience including use employee surveys results surveys play key role determining direction culture well companys broader response emerging developments example response covid pandemic provided meaningful benefits employees refined approach flexible work arrangements believe flexible work program positions us competitive talent support employee wellbeing also creating collaborative environment connections fuel innovation environmental social governance esg investing corporate responsibility core business strategy reflects values accountability inclusion teamwork excellence integrity service mission advance global health providing innovative therapeutics areas unmet need way socially responsible environmentally sustainable gileads esg programs reflect commitment stakeholders esg strategy performance overseen nominating corporate governance committee board directors managed corporate responsibility committee comprised leaders key departments across company corporate responsibility committee responsible reviewing esg issues appropriate integrating overall business strategy operations additional information program esg highlights available gileads year review gileads website httpswwwgileadcommediafilespdfsyirpdfsgileadyirdesktoppdf esg goals aspirational may change statements regarding goals related initiatives guarantees promises met seasonality operations worldwide product sales reflect significant degree seasonality enduser demand however us fluctuations wholesaler inventory levels impact product sales typically observe strong wholesaler subwholesaler purchases products fourth quarter resulting inventory drawdown wholesalers subwholesalers subsequent first quarter several factors including government budgets annual grant cycles federal state funds adverse changes economic conditions increased competition buying patterns also could impact product sales recorded particular quarter information see item risk factors face challenges accurately forecasting sales difficulties predicting demand products fluctuations purchasing patterns wholesaler inventories government regulation operations activities subject extensive regulation numerous government authorities us eu countries including laws regulations governing testing manufacture safety efficacy labeling storage record keeping approval advertising promotion products result regulations product development product approval processes expensive time consuming significant impact capital expenditures results operations regulatory requirements applicable drug development approval subject change legal regulatory changes may impact operations future countrys regulatory agency fda us ema ec eu well national authorities eu member states must approve drug sold respective country countries general process drug approval us summarized many countries including countries eu eu centralized procedure similar regulatory structures preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drug candidates potential benefits safety submit data fda investigational new drug ind application seeking approval test compound humans clinical trials fda accepts ind drug candidate studied human clinical trials determine drug candidate safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug candidate given small number healthy human control subjects patients suffering risk indicated disease test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug candidate given limited patient population determine effect drug candidate treating preventing disease best dose drug candidate possible side effects safety risks drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous extensive phase clinical trials phase drug candidate appears effective appropriate safety profile phase clinical trials phase clinical trials commenced confirm results phase clinical trials conducted longer term involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous extensive phase clinical trials fda approval process believe data clinical trials show acceptable benefitrisk profile submit appropriate filing usually form new drug application biologics license application supplemental application fda seeking approval sell drug candidate particular use fdas discretion fda may hold public hearing independent advisory committee expert advisors asks additional questions makes recommendations regarding drug candidate committee makes recommendation fda binding generally followed fda fda agrees drug met required level safety efficacy particular use approve application allow us sell drug us use unusual however fda decline approve application believes drug candidate safe enough efficacious enough ie appropriate benefitrisk profile believe data submitted reliable conclusive point process development drug candidate stopped number reasons including safety concerns lack treatment benefit manufacturing issues certain clinical trials currently conducting conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit even approving drug fda may also require phase nonregistrational studies explore scientific questions characterize safety efficacy commercial use drug fda may also require us provide additional data information improve manufacturing processes procedures facilities may require extensive surveillance monitor safety benefits product candidates determines filing contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug fda withdraw approvals believe complying regulatory standards concerns safety efficacy uncovered occur approval addition obtaining fda approval drug obtain fda approval manufacturing facilities drug sell including companies manufacture drugs us facilities subject periodic inspections fda fda must also approve foreign establishments manufacture products sold us facilities subject periodic regulatory inspection manufacturing facilities located california also must licensed state california compliance local regulatory requirements manufacturing facilities canada ireland netherlands also must obtain local licenses permits compliance local regulatory requirements fda may employ one several tools facilitate expedite development review drug including fast track designation breakthrough therapy designation accelerated approval designation priority review designation fast track designation designed facilitate development review drug treats serious condition fills unmet medical need breakthrough therapy designation designed expedite development review drug treats serious condition preliminary clinical evidence demonstrates substantial improvement available therapies accelerated approval drug may granted fda drug treats serious condition fills unmet medical need studied safety efficacy priority review designation means fdas goal take action application within six months filing fda may grant priority review designation drug would provide significant improvement safety effectiveness treatment diagnosis prevention serious condition eu regulatory system approval process eu products subject variety eu eu member state regulations governing clinical trials commercial sales distribution required obtain marketing authorization eu market medicinal products relevant market conduct clinical trials eu governed among others directive ec directive ec eu ich good clinical practice rules impose legal regulatory obligations similar provided applicable us laws conduct clinical trials eu must approved competent authorities eu member states clinical trials take place positive opinion must obtained relevant ethics committee relevant member state eu legislator adopted regulation eu replace directive ec introduce coordinated procedure authorization clinical trials regulation entered application january marketing authorization holders manufacturers importers wholesalers distributors medicinal products placed market eu required comply number regulatory requirements including pharmacovigilance gmp compliance requirement obtain manufacturing import andor distribution licenses issued competent authorities eu member states failure comply requirements may lead imposition civil criminal administrative sanctions including suspension marketing manufacturing authorizations pricing reimbursement successful commercialization products depends part availability thirdparty payer reimbursement cost products related treatments medical services markets sell products government health authorities private health insurers organizations generally provide reimbursement us eu significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services significant portion sales majority products subject substantial discounts list prices including rebates may required pay medicaid agencies discounts may required pay covered entities section b public health service act b result price increases implement time time certain products may limited effect net product sales certain markets addition standard reimbursement structures may adequately reimburse innovative therapies products mature pricing pressures private insurers government payers often result reduction net product prices new branded generic products introduced major markets ability maintain pricing market share may affected information see item risk factors existing products subject reimbursement pressures government agencies third parties required rebates discounts products pricing pressures face challenges accurately forecasting sales difficulties predicting demand products fluctuations purchasing patterns wholesaler inventories health care fraud abuse laws antibribery laws subject various us federal state laws pertaining health care fraud abuse including antikickback laws false claim laws anti kickback laws make illegal prescription drug manufacturer knowingly willingly solicit offer receive pay remuneration exchange induce referral business reimbursed federal healthcare program including purchase prescription particular drug false claims laws generally prohibit anyone knowingly presenting causing presented false fraudulent claim payment federal certain state payers including medicare medicaid knowingly making using causing made used false record statement material false fraudulent claim addition fda regulates written verbal communications products addition federal law states also consumer protection false claims laws due breadth statutory provisions attention given law enforcement authorities sales marketing patient support medical clinical public affairs activities may subject scrutiny laws example recently enhanced scrutiny government enforcement authorities companysponsored patient assistance programs including copay assistance programs manufacturer donations thirdparty charities provide assistance reimbursement support offerings clinical education programs promotional speaker programs similarly europe interactions pharmaceutical companies physicians subject strict laws regulations industry selfregulation codes conduct physicians codes professional conduct applicable including eu member states anticorruption laws uk bribery act addition us foreign corrupt practices act similar worldwide antibribery laws generally prohibit companies intermediaries making improper payments purpose obtaining retaining business policies mandate compliance antibribery laws operate parts world experienced governmental corruption degree certain circumstances strict compliance antibribery laws may conflict local customs practices may require us interact doctors hospitals may state controlled manner different local custom despite training compliance program internal control policies procedures may protect us unlawful acts committed employees agents violations fraud abuse laws antibribery laws may punishable criminal andor civil sanctions including fines civil monetary penalties well possibility exclusion federal health care programs including medicare medicaid violations also lead imposition corporate integrity agreement similar government oversight program even disagree governments perspective violated rules guidance similar violations competitors could also negatively impact reputation industry increase governmental public scrutiny business products information see item risk factors impacted evolving laws regulations legislative regulatory actions applicable health care industry environment subject number laws regulations require compliance federal state local regulations protection environment regulatory landscape continues evolve anticipate additional regulations future laws regulations implemented consideration mitigate effects climate change mainly caused greenhouse gas emissions business energy intensive therefore anticipate subject cap trade system mitigation measure would materially impact capital expenditures operations competitive position information subject information requirements securities exchange act exchange act therefore file periodic reports proxy information statements information us securities exchange commission sec sec maintains website wwwsecgov contains reports proxy information statements information regarding issuers file electronically sec website wwwgileadcom link investors website financials sec filings section make available following filings free charge soon reasonably practicable electronically filed furnished sec annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section exchange act website references provided throughout document convenience content referenced websites constitute part incorporated reference annual report item risk factors evaluating business carefully consider following discussion material risks events uncertainties make investment us speculative risky addition information annual report manifestation following risks uncertainties could circumstances may may able accurately predict materially adversely affect business operations growth reputation including commercial scientific reputation products prospects product pipeline sales operating financial results financial condition cash flows liquidity stock price note factors investors permitted private securities litigation reform act possible predict identify factors operations could also affected factors events uncertainties presently known us currently consider present significant risks operations therefore consider following risks complete statement potential risks uncertainties face product commercialization risks certain products subject us additional heightened risks hiv receive substantial portion revenue sales products treatment prevention hiv infection year ended december sales hiv products accounted approximately total product sales may unable sustain increase sales hiv products number reasons including market share gains competitive products including generics inability introduce new hiv medications necessary remain competitive case may need scale back operations including future drug development spending research development rd efforts example many hiv products contain tenofovir alafenamide taf belongs nucleoside class antiviral therapeutics changes treatment prevention paradigm hiv cause nucleosidebased therapeutics fall favor hiv product sales would adversely impacted veklury face risks related supply distribution veklury approved us food drug administration fda october treatment patients hospitalized coronavirus disease covid january treatment nonhospitalized adult adolescent patients high risk progression severe covid including hospitalization death april treatment pediatric patients days age older weighing least kg either hospitalized covid mildtomoderate covid considered high risk progression severe covid including hospitalization death veklury sales generally reflect covid related rates severity infections hospitalizations well availability uptake effectiveness vaccines alternative treatments covid unable accurately predict revenues supply needs short longterm due dynamic nature covid pandemic accurately forecast demand manufacture veklury levels align actual demand may experience product shortages build excess inventory may need written also remain subject significant public attention scrutiny complex decisions made regarding clinical data supply allocation distribution pricing veklury affects corporate reputation cell therapy advancing novel personalized therapy yescarta tecartus chimeric antigen receptor car tcell therapies creates significant challenges including educating certifying medical personnel regarding procedures potential side effects cytokine release syndrome neurologic toxicities compliance risk evaluation mitigation strategy program required fda securing sufficient supply medications manage side effects tocilizumab corticosteroids may available sufficient quantities may adequately control side effects andor may detrimental impacts efficacy cell therapy developing maintaining robust reliable process engineering patients cells facilities infusing back patient conditioning patients chemotherapy advance administering therapy may increase risk adverse side effects use engineered cells potential cancer treatment recent development may broadly accepted physicians patients hospitals cancer treatment centers payers others medical community fda approved cell therapies including yescarta tecartus must continue demonstrate medical community potential advantages cell therapy compared existing future therapeutics challenges related reimbursement yescarta tecartus see also existing products subject reimbursement pressures government agencies third parties required rebates discounts products pricing pressures rely thirdparty sites collect patients white blood cells known apheresis centers well shippers couriers hospitals logistical collection patients white blood cells ultimate delivery yescarta tecartus patients vendors may encounter disruptions difficulties could result product loss regulatory action apheresis centers may also choose participate quality certification process may unable complete certification timely manner could delay constrain manufacturing commercialization efforts operate new automated car tcell therapy manufacturing facility frederick maryland received fda approval commercial production april previously manufactured products automated facility commercial scale result may require additional time resources order effectively increase manufacturing capacity also operate new retroviral vector manufacturing facility oceanside california received fda approval commercial production october also previously manufactured viral vectors commercial scale result may require additional time resources order effectively increase manufacturing capacity addition may able produce otherwise obtain amount viral vector supply sufficient satisfy demand finished products unable meet product demand difficulty meeting sales forecasts finished products success depends developing commercializing new products expanding indications existing products unable launch commercially successful new products new indications existing products business adversely impacted launch commercially successful products necessary grow business cover substantial rd expenses offset revenue losses existing products lose market share due factors competition loss patent exclusivity many difficulties uncertainties inherent drug development introduction new products product development cycle characterized significant investments resources long lead times unpredictable outcomes due nature developing medicines human use expend significant time resources product pipeline without assurance recoup investments efforts commercially successful high rate failure inherent discovery development new products failure occur point process including late process substantial investment face challenges accurately forecasting sales difficulties predicting demand products fluctuations purchasing patterns wholesaler inventories may unable accurately predict demand products including uptake new products demand depends number factors example product demand may adversely affected physicians see benefit products additionally nonretail sector us includes government institutions including state aids drug assistance programs us department veterans affairs correctional facilities large health maintenance organizations tends less consistent terms buying patterns often causes quarteroverquarter fluctuations mirror actual patient demand products federal state budget pressures well annual grant cycles federal state funds may cause purchasing patterns reflect patient demand products expect continue experience fluctuations purchasing patterns nonretail customers light budget crises faced many european countries observed variations purchasing patterns induced cost containment measures europe believe measures caused government agencies purchasers reduce inventory products distribution channels may continue see trend future sell distribute products us exclusively wholesale channel year ended december approximately product sales us three wholesalers amerisourcebergen corporation cardinal health inc mckesson corporation us wholesalers entered inventory management agreements make estimates determine enduser demand may accurate matching inventory levels actual enduser demand result changes inventory levels held wholesalers cause operating results fluctuate unexpectedly sales wholesalers match enduser demand addition inventory held retail pharmacies nonwholesaler locations inventory management agreements control buying patterns adverse changes economic conditions increased competition factors may cause retail pharmacies reduce inventories products would reduce orders wholesalers consequently wholesalers orders us even enduser demand changed addition observed strong wholesaler subwholesaler purchases products fourth quarter typically results inventory drawdown wholesalers subwholesalers subsequent first quarter inventory distribution channel fluctuates quarter quarter may continue see fluctuations earnings mismatch prescription demand products revenues face significant competition global pharmaceutical biotechnology companies specialized pharmaceutical firms generic drug manufacturers new branded generic products entering major markets affects ability maintain pricing market share products compete available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance ease use price insurance reimbursement coverage distribution marketing number companies pursuing development products technologies may competitive existing products research programs competing companies include large pharmaceutical biotechnology companies specialized pharmaceutical firms acting either independently together companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs may adversely impacted competitors gain market share result new technologies commercialization strategies otherwise existing products subject reimbursement pressures government agencies third parties required rebates discounts products pricing pressures product reimbursements successful commercialization products depends part availability amount thirdparty payer reimbursement products related treatments medical services markets sell products products mature pricing pressures private insurers government payers often result reduction net product prices legislative regulatory actions affecting government prescription drug procurement reimbursement programs occur relatively frequently example september fda issued final rule implementing pathway importation certain prescription drugs canada rule subject ongoing litigation may adversely impacted legislative regulatory actions though difficult predict impact use reimbursement products product pricing discounts rebates us european union eu significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services volume drug pricingrelated legislation dramatically increased recent years including us congress enacted laws requiring manufacturer refunds certain amounts discarded drug singleuse vials beginning eliminating existing cap medicaid rebate amounts beginning us congress enacted inflation reduction act act among changes requires department health human services negotiate medicare prices certain drugs starting drugs adding drugs adding drugs subsequent years imposes inflationbased rebate medicare part b utilization starting part utilization beginning october restructures medicare part benefit cap outofpocket expenses part beneficiaries beginning effective january increases part plans contributions catastrophic coverage phase increase manufacturers discount contributions across coverage phases manufacturers must pay discount initial coverage phase discount catastrophic phase drugs utilized part beneficiaries including low income subsidy patients continue evaluate impact act business expect act increase payment obligations redesigned part discount program limit prices charge increase rebates must provide government programs products thereby reducing profitability negatively impacting financial results addition unclear certain provisions act implemented may additional legislation rulemaking related act select provisions may become subject legal challenges future therefore full impact act profitability business pharmaceutical industry whole remains uncertain time many state legislatures considering already passed law legislation seeks indirectly directly regulate pharmaceutical drug pricing requiring manufacturers publicly report proprietary pricing information creating review boards prices encouraging use generic drugs initiatives legislation may cause added pricing pressures products resulting impact business uncertain many countries outside us including eu member states established complex lengthy procedures obtain price approvals coverage reimbursement periodically review pricing reimbursement decisions outcome reviews predicted could adverse effect pricing reimbursement medical products eu member states reductions pricing medical products one member state could affect price member states negative impact financial results substantial portion product sales subject significant discounts list price including rebates may required pay state medicaid agencies discounts provided covered entities section b public health service act b changes b program medicaid program federal state level could material adverse effect business example continued growth b program limits prices may charge increasing percentage sales changes calculation rebates medicaid program could substantially increase medicaid rebate obligations decrease prices charge bcovered entities recently implemented contract pharmacy integrity initiative branded hepatitis c virus hcv products integrity initiative involve products asegua therapeutics llc integrity initiative requires covered entities enter b bill toship arrangements contract pharmacies branded hcv products provide claims level data units dispensed contract pharmacies covered entities without inhouse pharmacy choose participate initiative designate single contract pharmacy shipment certain manufacturers implemented contract pharmacy integrity programs received enforcement letters us department health human services hhs asserting programs violate b statute referred hhs office inspector general assessment civil monetary penalties subject administrative dispute resolution proceedings brought behalf covered entities manufacturers currently challenging hhs position ongoing litigation although believe integrity initiative complies requirements b statute additional legal legislative developments respect b program including potential litigation hhs may negatively impact ability implement continue integrity initiative addition standard reimbursement structures may adequately reimburse innovative therapies example beginning fiscal year cms established new severityadjusted diagnosisrelated group drg medicare inpatient reimbursement car tcell products yescarta tecartus new drg significantly higher base payment amount prior drg payment available may sufficient reimburse hospitals cost care patients receiving yescarta tecartus reimbursement aligned well account treatment costs medicare beneficiaries may denied access misalignment could impact willingness hospitals offer therapy doctors recommend therapy additionally eu barriers reimbursement individual countries could limit uptake yescarta tecartus moreover estimate rebates required pay connection sales particular quarter based claims data prior quarters us actual rebate claims typically made payers one three quarters arrears actual claims payments may vary significantly estimates may experience adverse impacts resulting importation products lower price markets distribution illegally diverted counterfeit versions products prices products based local market economics competition sometimes differ country country sales countries relatively higher prices may reduced products imported resold countries lower price markets example us sales could also affected fda permits importation drugs canada entered agreements generic drug manufacturers well licensing agreements medicines patent pool united nationsbacked public health organization allow generic drug manufacturers manufacture generic versions certain products distribution certain low middleincome countries may adversely affected generic versions products whether produced andor distributed agreements exported us eu markets higher prices eu required permit products purchased one eu member state sold another member state purchases products member states selling prices relatively low resale member states selling prices relatively high affect inventory level held wholesalers cause relative sales levels various countries fluctuate quarter quarter reflect actual consumer demand given quarter additionally diverted products may used countries approved patients may source diverted products outside legitimate supply chain diverted products may handled shipped stored inappropriately may affect efficacy products could harm patients adversely impact us also aware existence various suppliers around world without gileads authorization purport source products generic versions products sell use countries products approved result patients may risk taking unapproved medications may purport may potency claim may contain harmful substances could harm patients adversely impact us third parties illegally distributed sold may continue illegally distribute sell illegally diverted counterfeit versions medicines meet rigorous quality standards manufacturing supply chain example part us civil enforcement lawsuit coordination law enforcement pursuant court order seized thousands bottles gileadlabeled medication counterfeit supply chain documentation investigation revealed pharmaceutical distributors authorized gilead sell gilead medicine sold purportedly genuine gilead medicine sourced illegal counterfeiting scheme independent pharmacies nationwide illegally diverted counterfeit versions gileadbranded medicines exist may pose serious risk patient health safety actions stop prevent distribution sale illegally diverted counterfeit versions medicines around world may costly unsuccessful may adversely affect patients reputation business including product revenues financial results product development supply chain risks face risks clinical trials including potential unfavorable results delays anticipated timelines disruption required demonstrate safety efficacy product candidates develop intended use extensive preclinical studies clinical trials results studies always accurately predict results later largescale clinical trials even successfully completed largescale clinical trials may result marketable products face numerous risks uncertainties clinical trials could result delays prevent completion development approval product candidates including challenges clinical trial protocol design ability enroll patients clinical trials possibility unfavorable inadequate trial results support development product candidates including failure meet trials primary endpoint safety issues arising clinical trials need modify delay clinical trials perform additional trials example october announced fda issued complete response letter biologics license application bulevirtide treatment adults hepatitis delta virus infection addition see note goodwill intangible assets notes consolidated financial statements included part ii item annual report discussion partial inprocess research development impairment charge recognized three months ended march related assets acquired immunomedics inc immunomedics result may unable successfully complete clinical trials anticipated timelines based trial results possible fda regulatory authorities approve product candidates market approvals include significant limitations products use addition clinical trials involving commercial products raise new safety issues existing products could adversely impact business may make strategic decision discontinue development product candidates example believe commercialization difficult relative opportunities pipeline therefore product candidates may never successfully commercialized may unable recoup significant rd clinical trial expenses incurred expect expend significant time resources clinical trial activities without assurance recoup investments efforts commercially successful also risks associated use third parties clinical trial activities extensively outsource clinical trial activities usually perform small portion startup activities inhouse rely independent thirdparty contract research organizations cros perform clinical studies including document preparation site identification screening preparation prestudy visits training program management patient enrollment ongoing monitoring site management bioanalytical analysis many important aspects services performed us cros direct control dispute disruption relationship cros clinical trials may delayed moreover regulatory submissions rely quality validity clinical work performed thirdparty cros cros processes methodologies results determined invalid inadequate clinical data results related regulatory approvals may adversely affected may face manufacturing difficulties delays interruptions including thirdparty manufacturers corporate partners products manufactured facilities thirdparty manufacturers corporate partners result complex highly regulated manufacturing processes depend thirdparty manufacturers corporate partners perform manufacturing activities effectively timely basis majority active pharmaceutical ingredients drug products third parties independent entities subject unique operational financial risks control thirdparty manufacturers corporate partners subject good manufacturing practices gmp extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda european medicines agency ema well comparable regulations jurisdictions manufacturing operations also subject routine inspections regulatory agencies adverse developments affecting resulting manufacturing operations operations thirdparty manufacturers corporate partners may result shipment delays inventory shortages lot failures product withdrawals recalls interruptions commercial supply products incurred continue incur inventory writeoff charges expenses products fail meet specifications quality standards may need undertake costly remediation efforts seek costly manufacturing alternatives developments could increase manufacturing costs cause us lose revenues market share damage reputation addition manufacturing issues may cause delays clinical trials applications regulatory approval example unable remedy deficiencies cited fda regulatory agencies inspections existing products timing regulatory approval product candidates development could adversely affected risk regulatory agencies countries marketing applications pending undertake similar additional reviews apply heightened standard review could delay regulatory approvals products countries business may adversely affected approval product candidates delayed production products interrupted may able obtain materials supplies necessary conduct clinical trials manufacture sell products could limit ability generate revenues need access certain supplies products conduct clinical trials manufacture sell products unable purchase enough materials find suitable alternative materials timely manner development efforts product candidates may delayed ability manufacture sell products could limited suppliers key components materials must named new drug application marketing authorization application filed regulatory authority product candidate seeking marketing approval significant delays occur qualification new supplier required even manufacturer qualified regulatory authority manufacturer must continue expend time money effort area production quality control maintain full compliance gmp manufacturers subject regular periodic inspections regulatory authorities following initial approval result inspections regulatory authority determines equipment facilities laboratories processes comply applicable regulations conditions product approval regulatory authority may suspend manufacturing operations manufacturing operations single suppliers products suspended may unable generate sufficient quantities commercial clinical supplies product meet market demand addition deliveries materials suppliers interrupted reason may unable ship certain products commercial supply supply product candidates development clinical trials also products materials utilize operations manufactured one supplier one facility may able replace timely manner commercially reasonable terms problems single suppliers facilities depend including event disaster earthquake equipment failure difficulty may negatively impact development commercialization efforts significant portion raw materials intermediates used manufacture antiviral products supplied thirdparty manufacturers corporate partners outside us result political economic factors specific country region including changes interpretations trade regulations compliance requirements tax legislation would limit prevent third parties outside us supplying materials could adversely affect ability manufacture supply antiviral products meet market needs material adverse effect operating results encounter difficulties ability conduct clinical trials product candidates manufacture sell products could impaired regulatory legal risks operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis maintain compliance could delay halt commercialization products products develop must approved marketing sale regulatory authorities approved subject extensive regulation fda ema comparable regulatory agencies countries filed anticipate continue file marketing approval additional countries additional indications products future marketing applications file may approved regulatory authorities timely basis even marketing approval granted products may significant limitations use state certainty whether product candidates development approved launched whether able develop license acquire additional product candidates products whether products launched commercially successful manufacture sell products subject extensive regulation review example fda rules often required conduct postapproval clinical studies assess known serious risk signals serious risk identify unexpected serious risk certain circumstances may required implement risk evaluation mitigation strategy program products could include medication guide patient package insert communication plan healthcare providers restrictions distribution use product elements fda deems necessary assure safe use drug discovery previously unknown problems marketed products product candidates including serious safety resistance drug interaction issues problems manufacturing safety reporting promotional activities may result regulatory approvals delayed denied granted significant restrictions products including limitations withdrawal products market failure comply requirements imposed fda could result significant civil monetary penalties fines suspensions regulatory approvals product recalls seizure products criminal prosecutions impacted evolving laws regulations legislative regulatory actions applicable healthcare industry healthcare industry subject various federal state international laws regulations pertaining drug reimbursement rebates price reporting healthcare fraud abuse data privacy security us laws include antikickback false claims laws laws regulations relating medicare medicaid programs federal state programs medicaid rebate statute b statute laws regulate written verbal communications products individual state laws relating pricing sales marketing practices health insurance portability accountability act federal state laws relating privacy security health information actual alleged violations laws related regulations may punishable criminal andor civil sanctions including instances substantial fines civil monetary penalties exclusion participation federal state healthcare programs including medicare medicaid us department veterans affairs us department defense health programs actions executives overseeing business significant remediation measures negative publicity consequences laws regulations broad scope subject changing evolving interpretations could require us incur substantial costs associated compliance alter one sales marketing practices resulting impact business uncertain could material addition government price reporting payment regulations complex continually assessing methods calculate report pricing accordance obligations methodologies calculations inherently subjective may subject review challenge various government agencies may disagree interpretation government disagrees reported calculations may need restate previously reported data could subject additional financial legal liability also continues enhanced scrutiny companysponsored patient assistance programs including copay assistance programs manufacturer donations thirdparty charities provide assistance also enhanced scrutiny governments reimbursement patient support offerings clinical education programs promotional speaker programs agents vendors deemed failed comply laws regulations government guidance areas could subject criminal civil sanctions similar violations competitors could also negatively impact industry reputation increase scrutiny business products description government investigations related litigation see note commitments contingencies notes consolidated financial statements included part ii item annual report subject risks significant safety issues arise marketed products product candidates additional studies conducted obtaining marketing approval products products used longer periods time many patients including patients underlying health problems taking medicines expect continue finding new issues related safety resistance drug interactions issues may require changes product labels additional warnings contraindications even narrowed indications halt sales product regulatory authorities moving towards active transparent pharmacovigilance making greater amounts standalone safety information clinical trial data directly available public websites means periodic safety update report summaries risk management plan summaries various adverse event data safety information without appropriate context expertise may misinterpreted lead misperception legal action success depends significant degree ability obtain defend patents intellectual property rights domestically internationally operate without infringing upon patents proprietary rights third parties patents proprietary rights important business part business strategy actively seek patent protection us internationally file additional patent applications appropriate cover improvements compounds products technology success depends significant degree ability obtain patents licenses patent rights preserve trade secrets internal knowhow defend infringement patents efforts invalidate operate without infringing intellectual property others patent applications confidential period time filing may know competitors filed applications technology covered pending applications first invent first file application directed toward technology subject patent applications competitors file patent applications covering technology may participate litigation postgrant proceedings us patent trademark office proceedings determine right patent validity patent granted litigation proceedings unpredictable expensive could divert management attention operations even ultimately successful may adversely impacted patents covering existing compounds products processes likely file future may provide complete adequate protection filing patent applications factintensive complex process may file patent applications ultimately result patents patents provide adequate protection related product future litigation proceedings regarding enforcement validity existing patents future patents could result invalidation patents substantially reduce protection addition may face criticism result legitimate use patent systems protect investments new useful innovations medicine generic manufacturers sought may continue seek fda approval market generic versions products abbreviated new drug application anda application process typically used manufacturers seeking approval generic drug description anda litigation see note commitments contingencies notes consolidated financial statements included part ii item annual report anda litigation related settlement license agreements cases may result loss exclusivity patents sooner would otherwise expect addition loss exclusivity may earlier expected settlement license agreements certain circumstances example settlement license agreements generic manufacturers typically include acceleration clauses permit generic entry agreedupon entry date certain circumstances generic manufacturers may continue challenge patents protecting products entry generic versions products may future lead market share price erosion found infringe valid patents third parties may required pay significant monetary damages may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license commercially reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware patents patent applications owned parties parties may claim cover use products research activities description pending patent litigation see note commitments contingencies notes consolidated financial statements included part ii item annual report furthermore also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation protect rights mainly confidentiality agreements corporate partners employees consultants vendors certain parties comply confidentiality agreements adequate remedies breach trade secrets internal knowhow technological innovation otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partner cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions could adversely affected trade secrets internal knowhow technological innovation confidential information become known independently discovered competitors enter disputes ownership inventions face potentially significant liability increased expenses litigation government investigations relating products operations involved number litigation investigation disputerelated matters require us expend substantial internal financial resources matters could require us pay significant monetary amounts including royalty payments past future sales example february reached agreement viiv healthcare company related parties collectively viiv global resolution claims related sales biktarvy pursuant gilead agreed make onetime payment billion ongoing royalty rate future sales biktarvy bictegravir component bictegravircontaining products us october viiv granted gilead broad worldwide license covenant sue relating past present future development commercialization bictegravir expect matters continue require high level internal financial resources foreseeable future matters reduced expected continue reduce earnings require significant management attention addition testing manufacturing marketing use commercial products well product candidates development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others limited insurance product liabilities may arise claims may exceed coverage description litigation investigation disputerelated matters see note commitments contingencies notes consolidated financial statements included part ii item annual report outcome legal proceedings legal proceedings may brought us investigations investigations may initiated disputerelated matters inherently uncertain adverse developments outcomes result significant expenses monetary damages penalties injunctive relief us operational risks business may future adversely affected outbreaks epidemic pandemic contagious diseases including ongoing covid pandemic actual threatened outbreaks epidemic pandemic contagious diseases public health emergencies may significantly disrupt global operations adversely affect business financial condition results operations seen covid pandemic outbreaks result global supply chain logistics disruptions distribution constraints impact outbreak public health crisis results operations financial condition would depend numerous evolving factors could involve higher operating expenses lower demand products result governmental business individuals actions taken response event including quarantines travel restrictions interruptions healthcare services impact enrollment operation clinical trials limit patients ability willingness access seek care challenges associated safety employees safe occupancy job sites financial market volatility significant macroeconomic uncertainty global markets outbreak public health emergency also could amplify many risks described throughout risk factors section annual report face risks associated global operations global operations accompanied certain financial political economic risks including listed foreign currency exchange year ended december approximately product sales outside us significant percentage product sales denominated foreign currencies primarily euro face exposure adverse movements foreign currency exchange rates overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar hedging program eliminate exposure currency fluctuations may adversely impacted us dollar appreciates significantly certain currencies hedging program sufficiently offset effects appreciation example see part ii item annual report discussion exposure movements foreign currency exchange rates primarily euro impacts foreign currency exchange net hedges year ended december interest rates inflation hold interestgenerating assets interestbearing liabilities including availableforsale debt securities senior unsecured notes credit facilities fluctuations interest rates including us federal reserves recent increases interest rates could expose us increased financial risk addition high inflation seeing current economic environment adversely impacted may continue adversely impact business financial results antibribery subject us foreign corrupt practices act similar worldwide antibribery laws govern international operations respect payments government officials international operations heavily regulated require significant interaction foreign officials operate parts world experienced governmental corruption degree certain circumstances strict compliance antibribery laws may conflict local customs practices may require us interact doctors hospitals may statecontrolled manner different local custom possible certain practices may challenged laws addition internal control policies procedures may protect us reckless criminal acts committed employees agents enforcement activities antibribery laws could subject us administrative legal proceedings actions could result civil criminal sanctions including monetary penalties exclusion healthcare programs risks inherent conducting global business include restrictive government actions intellectual property foreign assets nationalization expropriation imposition compulsory licenses similar actions including waiver intellectual property protections protective economic policies taken foreign governments trade protection measures import export licensing requirements may result imposition trade sanctions similar restrictions us governments business interruptions stemming natural manmade disasters climate change earthquakes hurricanes flooding fires extreme heat drought actual threatened public health emergencies efforts taken third parties prevent mitigate disasters public safety power shutoffs facility shutdowns may sufficient insurance example corporate headquarters foster city certain rd manufacturing facilities located california seismically active region event major earthquake may carry sufficient earthquake insurance significant recovery time could required resume operations political instability disruption geographic region operate regardless cause including war terrorism social unrest political changes including china russia ukraine aspirations goals disclosures related environmental social governance esg matters expose us numerous risks including risks reputation stock price institutional individual investors increasingly using esg screening criteria determine whether gilead qualifies inclusion investment portfolios frequently asked investors stakeholders set ambitious esg goals provide new robust disclosure goals progress toward goals matters interest esg stakeholders response adapted tracking reporting corporate responsibility program various evolving esg frameworks established announced goals objectives related esg matters goal statements reflect current plans aspirations guarantees able achieve efforts accomplish accurately report goals objectives present numerous operational reputational financial legal risks could material negative impact including reputation stock price ability achieve goal objective including respect environmental diversity initiatives subject numerous risks many outside control examples risks include availability cost low noncarbonbased energy sources technologies evolving regulatory requirements affecting esg standards disclosures availability suppliers meet sustainability diversity standards ability recruit develop retain diverse talent labor markets impact organic growth acquisitions dispositions businesses operations standards tracking reporting esg matters relatively new harmonized continue evolve selection disclosure frameworks seek align various reporting standards may change time time may result lack consistent meaningful comparative data period period addition regulatory authorities may impose mandatory disclosure requirements respect esg matters example march us securities exchange commission sec proposed rule changes would require companies make certain climaterelated disclosures including information climaterelated risks greenhouse gas emissions certain climaterelated financial statement metrics processes controls may reflect evolving standards identifying measuring reporting esg matters immediately interpretation reporting standards may differ others standards may change time could result significant revisions goals reported progress achieving goals addition enhancements processes controls reflect evolving reporting standards may costly require additional resources esg practices meet evolving investor stakeholder expectations standards reputation ability attract retain employees attractiveness investment business partner acquiror could negatively impacted similarly failure perceived failure pursue fulfill goals targets objectives satisfy various reporting standards within timelines announce could also similar negative impacts expose us government enforcement actions private litigation depend relationships third parties sales marketing performance technology development logistics commercialization products failure maintain relationships poor performance companies disputes third parties could negatively impact business rely number collaborative relationships third parties sales marketing performance certain territories countries rely international distributors sales certain products relationships also involve clinical development products partners reliance collaborative relationships poses number risks including risk unable control resources corporate partners devote programs products disputes may arise respect ownership rights technology developed corporate partners disagreements corporate partners could cause delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose pursue competing technologies devote fewer resources marketing products products development distributors corporate partners may unable pay us given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenues products could decline due specialized technical nature business failure attract develop retain highly qualified personnel could adversely impact us future success depend large part continued ability attract develop retain highly qualified scientific technical management personnel well personnel expertise clinical testing governmental regulation commercialization ability also depends part well maintain strong workplace culture attractive employees addition competition qualified personnel biopharmaceutical field intense limited pool qualified potential employees recruit face competition personnel companies universities public private research institutions government entities organizations additionally changes us immigration work authorization laws regulations could make difficult employees work transfer one jurisdictions operate significant cybersecurity incidents could give rise legal liability regulatory action data protection privacy laws adversely affect business operations dependent upon information technology systems infrastructure data including kite konnect platform critical maintain chain identity chain custody yescarta tecartus multitude complexity computer systems make inherently vulnerable service interruption destruction malicious intrusion ransomware attack likewise data privacy cybersecurity incidents breaches employees others result exposure sensitive data including intellectual property trade secrets personal information employees patients customers business partners unauthorized persons public cybersecurity attacks incidents increasing frequency sophistication intensity malicious actors seek steal money gain unauthorized access destroy manipulate data disrupt operations attacks may recognized discovered launched initial entry environment novel zeroday attacks launched patches available defenses readied malicious actors also increasingly developing methods avoid prevention detection alerting capabilities including employing counterforensic tactics making response activities difficult attacks incidents include example deployment harmful malware ransomware denialofservice social engineering means affect service reliability operations threaten data confidentiality integrity availability business technology partners face similar risks security breach systems could adversely affect security posture like many companies experienced cybersecurity incidents including data breaches service interruptions cybersecurity incidents occur policy respond address accordance applicable governmental regulations legal requirements including cybersecurity protocols assurance efforts response cybersecurity incidents well investments protect information technology infrastructure data shield us significant losses brand reputational harm potential liability prevent future interruption breach systems cybersecurity incidents cause loss critical sensitive information including personal information could give rise legal liability regulatory action data protection privacy laws regulators globally also imposing new data privacy security requirements including new greater monetary fines privacy violations example general data protection regulation gdpr established regulations regarding handling personal data noncompliance gdpr may result monetary penalties four percent worldwide revenue addition new domestic data privacy security laws california consumer privacy act california privacy rights act laws may passed similarly introduce requirements respect personal information noncompliance laws may result liability private actions subject statutorily defined damages event certain data breaches enforcement changes new laws regulations associated enhanced protection personal information could greatly increase cost providing products services even prevent us offering certain services jurisdictions operate strategic financial risks subject risks associated engaging business acquisitions licensing arrangements collaborations options equity investments asset divestitures strategic transactions engaged may future engage transactions part business strategy may identify suitable transactions future may complete transactions timely manner costeffective basis including possibility governmental entity regulatory body may delay refuse grant approval consummation transaction successful making acquisition closing licensing arrangement collaboration products intellectual property technologies acquired licensed may successful may require significantly greater resources investments anticipated part annual impairment testing goodwill indefinitelived intangible assets fourth quarter earlier impairment indicators exist required us generally accepted accounting principles may need recognize impairment charges related products intellectual property technologies acquired licensed example result impairment analysis conducted following receipt data march phase tropics study evaluating trodelvy patients hormone receptorpositive human epidermal growth receptor negative metastatic breast cancer recognized partial inprocess research development impairment charge consolidated statements income option structured deals assurance elect exercise option right possible disagreements uncertainties circumstances may arise including respect whether option rights appropriately triggered may hinder ability realize expected benefits equity investments strategic partners connection collaborations arcus biosciences inc galapagos nv value equity investments may fluctuate decline value successful execution implementation transactions financial condition cash flows results operations may adversely affected stock price could decline paid substantial amounts cash incurred additional debt finance strategic transactions additional indebtedness lower cash balance could result downgrade credit ratings limit ability borrow additional funds refinance existing debt favorable terms increase vulnerability adverse economic industry conditions reduce financial flexibility continue capital investments stock repurchases dividend payments example result cash used debt issued connection acquisition immunomedics sp global ratings downgraded credit rating may adversely impacted failure overcome additional risks changes effective income tax rate could reduce earnings subject income taxes us various foreign jurisdictions due economic political conditions various countries actively considering made changes existing tax laws predict form timing changes effective tax rates affected changes mix earnings countries differing statutory tax rates changes valuation deferred tax assets liabilities introduction new taxes changes tax laws regulations administrative practices interpretations including us germany ireland also subject examination tax returns tax matters us internal revenue service tax authorities various foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions may adversely affected resolution one exposures reporting period item b unresolved staff comments applicable item properties corporate headquarters located foster city california house administrative manufacturing rd activities also administrative facilities raleigh north carolina washington dc rd facilities emeryville oceanside santa monica california seattle washington frederick maryland morris plains new jersey edmonton canada dublin ireland principal manufacturing facilities el segundo la verne oceanside san dimas california edmonton canada cork ireland hoofddorp netherlands information manufacturing facilities see item business manufacturing facilities global operations include offices europe north america asia south america africa australia middle east believe existing properties including owned leased sites adequate suitable conduct business believe capital resources sufficient purchase lease construct additional facilities required meet expected longterm growth needs item legal proceedings description significant pending legal proceedings see note commitments contingencies legal proceedings notes consolidated financial statements included part ii item annual report item mine safety disclosures applicable part ii item market registrants common equity related stockholder matters issuer purchases equity securities market information common stock traded nasdaq global select market symbol gild holders february approximately stockholders record common stock dividends years ended december paid quarterly dividends expect continue pay quarterly dividends although amount timing future dividends subject declaration board directors additional information included note stockholders equity notes consolidated financial statements included item annual report securities authorized issuance equity compensation plans following table provides certain information respect equity compensation plans effect december number common shares remaining available future number common shares weightedaverage issuance equity issued upon exercise exercise price compensation plans outstanding options outstanding options excluding securities millions except per share amounts rights rights reflected column plan category b c equity compensation plans approved security holders equity incentive plan employee stock purchase plan total equity compensation plans approved security holders equity compensation plans approved security holders total includes million restricted stock units performance share units phantom shares awards exercise price included weightedaverage exercise price outstanding awards employee stock purchase plan participants permitted purchase common stock discount certain dates payroll deductions within predetermined purchase period accordingly numbers determinable performance graph following graph compares cumulative total stockholder return past five years two indices standard poors stock index sp index nasdaq biotechnology index nbi index stockholder return shown graph necessarily indicative future performance make endorse predictions future stockholder returns comparison cumulative total return investment past five years section soliciting material deemed filed securities exchange commission sec incorporated reference filings securities act amended securities act securities exchange act exchange act whether made date hereof irrespective general incorporation language filing shows cumulative return investment assuming investment common stock nbi index sp index december assuming dividends reinvested issuer purchases equity securities first quarter board directors authorized new billion stock repurchase program program fixed expiration purchases program may made open market privately negotiated transactions billion stock repurchase program authorized board directors first quarter program completed fourth quarter started repurchases program december december remaining authorized repurchase amount program billion table summarizes stock repurchase activity three months ended december maximum fair maximum fair total number value shares value shares total number shares purchased may yet may yet shares average part publicly purchased purchased purchased price paid announced program program program thousands per share thousands millions millions october october november november december december total difference total number shares purchased total number shares purchased part publicly announced program due shares common stock withheld us employee restricted stock awards order satisfy applicable tax withholding obligations item reserved item managements discussion analysis financial condition results operations following discussion analysis intended provide material information around events uncertainties known management relevant assessment financial condition results operations gilead therefore read conjunction audited consolidated financial statements accompanying notes consolidated financial statements disclosures included annual report form k including disclosures part item risk factors material events uncertainties otherwise discussed disclosed certain amounts percentages herein may sum recalculate due rounding additional information related comparison results operations years included item managements discussion analysis financial condition results operations form k filed us securities exchange commission sec management overview strategy outlook gilead sciences inc gilead us biopharmaceutical company pursued achieved breakthroughs medicine three decades goal creating healthier world people committed advancing innovative medicines prevent treat lifethreatening diseases including hiv viral hepatitis cancer operate countries worldwide headquarters foster city california since strategic ambitions bring transformative therapies patients ii biotech employer partner choice iii deliver shareholder value sustainable responsible manner strategic priorities beyond reflecting plan deliver ambitions maximize nearterm revenue growth ii maximize impact longactive hiv iii expand deliver oncology programs iv champion environment inclusion employee growth v remove barriers speed execution plan provide consistent execution portfolio quality depth breadth including continued growth leading hiv portfolio poised shape longacting market following first lenacapavir approvals well strong commercial performance clinical momentum fast growing oncology business key business updates continued advance portfolio receiving approvals across various therapeutic areas indications geographies ended year sunlenca receiving first approval us heavilytreatment experienced individuals following first european market approval european commission ec first twiceyearly subcutaneous hiv medicine approved also continued broaden therapies available oncology receiving approvals additional indications yescarta tecartus approval trodelvy treatment adult patients unresectable locally advanced metastatic hormone receptorpositive human epidermal growth factor receptor negative hrher breast cancer received endocrinebased therapy least two additional systemic therapies metastatic setting terms capital resources continued invest business research development rd pipeline acquisitions collaborations also continued provide shareholder returns form dividends share repurchases following highlights taken press releases recently issued readers encouraged review press releases available website wwwgileadcom content referenced website constitute part incorporated reference annual report virology december announced us food drug administration fda approval sunlenca combination antiretrovirals treatment hiv infection heavily treatmentexperienced adults multidrug resistant hiv infection november announced ec authorized extended indication line extension lowdosage tablet form biktarvy treatment hiv virologically suppressed children least years age weigh least kg november announced fda approval vemlidy treatment chronic hepatitis b virus hbv infection pediatric patients years older compensated liver disease october announced merck co inc merck gilead plan resume phase study amended protocol study evaluate investigational onceweekly oral combination treatment regimen mercks islatravir lower weekly dose gileads lenacapavir august announced ec granted marketing authorization sunlenca lenacapavir treatment hiv infection combination antiretrovirals adults multidrug resistant hiv infection otherwise possible construct suppressive antiviral regimen july received positive opinion european medicines agencys ema committee medicinal products human use chmp veklury granted full marketing authorization treatment coronavirus disease covid adults adolescents pneumonia requiring supplemental oxygen adults require supplemental oxygen increased risk developing severe covid may announced fda lifted clinical hold placed investigational new drug application evaluate injectable lenacapavir hiv treatment preexposure prophylaxis following agencys review storage compatibility data lenacapavir injection alternate vial made aluminosilicate glass april fda approved supplemental new drug application veklury treatment pediatric patients years age treatment covid oncology cell therapy december entered agreement acquire tmunity therapeutics inc tmunity clinical stage private biotech company provide us preclinical clinical programs including armored car technology platform potential applied variety car ts enhance antitumor activity well rapid manufacturing processes transaction closed february december entered strategic collaboration arcellx inc arcellx codevelop cocommercialize cartddbcma latestage clinical asset development treatment multiple myeloma transaction closed january december announced transfer marketing authorization yescarta japan daiichi sankyo co ltd gilead kk december received approval ministry health labour welfare japan yescarta initial treatment relapsed refractory rr large bcell lymphoma lbcl october received european marketing authorization yescarta use adults secondline diffuse lbcl additionally ec granted marketing authorization tecartus treatment adult rr bcell precursor acute lymphoblastic leukemia canada received conditional marketing authorization yescarta rr follicular lymphoma fl two lines systemic therapy july received positive opinion emas chmp tecartus treatment adult patients years age rr bcell precursor june ec approved yescarta treatment adult patients rr fl three lines systemic therapy april fda approved commercial production new car tcell therapy manufacturing facility frederick maryland april fda granted approval yescarta initial treatment adults lbcl refractory relapses within months firstline chemoimmunotherapy february announced fda approved trodelvy treatment adult patients unresectable locally advanced metastatic hrher breast cancer received endocrinebased therapy least two additional systemic therapies metastatic setting january announced ema validated type ii variation marketing authorization application trodelvy treatment adult patients unresectable metastatic hrher breast cancer received endocrinebased therapy least two additional systemic therapies metastatic setting december acquired remaining rights gs anticcr antibody developed jounce therapeutics inc jounce treatment solid tumors october announced strategic collaboration macrogenics inc macrogenics develop bispecific antibodies treat various cancers agreement includes upfront payment us million macrogenics exclusive option granted us mgd investigational cd cd bispecific august announced agreement everest medicines everest transfer development commercialization rights gilead trodelvy greater china south korea asian markets april entered strategic research collaboration agreement dragonfly therapeutics inc dragonfly develop natural killer cell engagerbased immunotherapies oncology inflammation indications march announced results phase tropics study evaluating trodelvy patients hrher mbc received prior endocrine therapy cyclindependent kinase cdk inhibitors two four lines chemotherapy inflammation january announced collaboration licensing agreement evoq therapeutics inc evoq advance evoqs proprietary nanodisc technology treatment rheumatoid arthritis lupus september completed acquisition mirobio ltd mirobio million cash mirobio ukbased biotechnology company focused restoring immune balance agonists targeting immune inhibitory receptors key financial results millions except percentages per share amounts change total revenues net income attributable gilead diluted earnings per share attributable gilead total revenues billion remained relatively flat compared primarily due increased sales hiv cell therapy trodelvy offset lower sales veklury net income attributable gilead billion diluted earnings per share attributable gilead compared billion diluted earnings per share attributable gilead decrease primarily due following items net related tax effect partial inprocess research development iprd impairment charge billion three months ended march related assets acquired immunomedics inc immunomedics million charge related termination trodelvy collaboration agreement everest higher rd expenses partially offset billion charge settlement related bictegravir litigation fourth quarter repeat results operations revenues following table summarizes periodoverperiod changes total revenues year ended december year ended december millions except percentages us europe international total us europe international total change product sales hiv veklury hcv hbvhdv cell therapy trodelvy total product sales royalty contract revenues total revenues see note revenues notes consolidated financial statements included item annual report disaggregation revenue product hiv hiv product sales increased billion compared primarily due continued higher demand biktarvy worldwide favorable pricing dynamics partially offset impact loss exclusivity truvada us channel inventory dynamics unfavorable foreign currency exchange impact part favorable pricing dynamics resulted shifts channel mix expect channel mix remain similar veklury veklury product sales decreased billion compared primarily due lower demand driven reduced hospitalization rates us europe partially offset higher demand international sales veklury generally reflect covid related rates severity infections hospitalizations well availability uptake effectiveness vaccinations alternative treatments covid result future sales veklury difficult predict may vary significantly one period next hcv hcv product sales decreased billion compared primarily due unfavorable foreign currency exchange impact fewer patient starts unfavorable pricing dynamics hbv hdv hbv hdv product sales increased million compared primarily due higher demand vemlidy continued adoption hepcludex europe cell therapy cell therapy product sales include yescarta tecartus increased billion compared primarily due higher demand yescarta rr lbcl us europe well tecartus rr mantle cell lymphoma trodelvy trodelvy product sales increased million compared primarily due continued adoption metastatic triplenegative breast cancer us europe product sales decreased million compared primarily due lower demand ambisome loss exclusivity letairis grosstonet deductions following table summarizes periodoverperiod changes grosstonet deductions millions except percentages change gross product sales grosstonet deductions rebates chargebacks sales returns discounts total grosstonet deductions gross product sales net product sales foreign currency exchange impact generally face exposure movements foreign currency exchange rates primarily euro use foreign currency exchange contracts hedge portion foreign currency exposures total product sales generated outside us respectively foreign currency exchange net hedges unfavorable impact total product sales million based comparison using foreign currency exchange rates costs expenses following table summarizes periodoverperiod changes costs expenses millions except percentages change cost goods sold product gross margin bps research development expenses acquired inprocess research development expenses inprocess research development impairment nm selling general administrative expenses nm meaningful product gross margin product gross margin increased compared primarily driven billion charge settlement related bictegravir litigation fourth quarter repeat increase partially offset higher royalty expenses driven biktarvy royalties reversal million litigation reserve third quarter repeat changes product mix research development expenses research development expenses increased million compared primarily due higher clinical development spend related mostly trodelvy arcus biosciences inc arcus collaboration well inflationary increases acquired inprocess research development expenses acquired inprocess research development expenses million primarily related million charge associated acquisition mirobio million charge associated dragonfly collaboration million charge associated jounce collaboration acquisition gs million charge associated macrogenics collaboration acquired inprocess research development expenses million primarily related million charge associated option exercised arcus collaboration see note acquisitions note collaborations arrangements notes consolidated financial statements included item annual report additional information inprocess research development impairment connection acquisition immunomedics allocated portion purchase price acquired iprd intangible assets approximately billion assigned iprd intangible assets related trodelvy treatment patients hrher breast cancer march received data phase tropics study evaluating trodelvy patients hrher mbc received prior endocrine therapy cdk inhibitors two four lines chemotherapy thirdline plus patients based evaluation study results connection preparation financial statements first quarter updated estimate fair value hrher iprd intangible asset billion march estimate fair value used probability weighted income approach discounts expected future cash flows present value expected cash flows included cash flows hrher mbc thirdline plus patients patients earlier lines therapy subject separate clinical studies revised discounted cash flows lower primarily due delay launch timing thirdline plus patients caused decrease market share assumptions based expected competitive environment changes plans assumptions related estimated cash flows patients earlier lines therapy determined revised estimated fair value carrying value asset result recognized partial impairment charge billion inprocess research development impairment consolidated statements income three months ended march remaining balance hrher iprd intangible asset time assessment related cash flows earlier lines therapy phase pivotal studies development addition revised cash flows related thirdline plus patient setting future events result adverse changes key assumptions used determining fair value including timing product launches information competitive landscape treatments indication changes probability technical regulatory success failure obtain anticipated regulatory approval discount rate among others additional impairments may recorded could material financial statements iprd impairment charges recorded selling general administrative expenses selling general administrative expenses increased million compared primarily due million charge associated termination trodelvy license collaboration agreement everest provided everest broad commercialization development rights trodelvy certain asia territories terminated existing agreement reacquired trodelvy rights territories spending increases included increased promotional marketing investing mostly trodelvy cell therapy well higher corporate activities inflationary increases slightly offset decrease donations gilead foundation compared interest expense income expense net following table summarizes periodoverperiod changes interest expense income expense net millions except percentages change interest expense income expense net interest expense decreased million compared primarily due lower outstanding debt balances changes income expense net compared primarily reflects higher interest income due rising interest rates partially offset higher net unrealized losses equity securities income taxes following table summarizes periodoverperiod changes income tax expense millions except percentages change income income taxes income tax expense effective tax rate effective tax rate decreased compared primarily due beneficial change jurisdictional mix income lower state taxes liquidity capital resources continually evaluate liquidity capital resources including access external capital ensure adequately efficiently finance operations liquidity cash cash equivalents marketable debt securities billion billion december respectively cash cash equivalents increased million december december following table summarizes cash flow activities millions net cash provided used operating activities investing activities financing activities effect exchange rate changes cash cash equivalents operating activities net cash provided operating activities derived adjusting net income noncash items changes operating assets liabilities net cash provided operating activities billion compared billion decrease primarily due billion payment made first quarter connection legal settlement related bictegravir litigation well higher income tax payments made higher operating expenses investing activities net cash used investing activities billion compared billion decrease primarily due lower net purchases marketable debt equity securities partially offset higher capital expenditures acquisitions financing activities net cash used financing activities billion compared billion utilized cash billion debt repayments billion dividend payments billion common stock repurchases utilized cash billion debt repayments billion dividend payments million common stock repurchases capital resources believe existing capital resources including cash cash equivalents marketable debt securities revolving credit facility supplemented cash flows generated operations adequate satisfy capital needs foreseeable future december material cash requirements consisted primarily repayment outstanding borrowings income tax payments including remaining obligations onetime repatriation transition tax tax cuts jobs act purchases inventory operating lease obligations capital expenditures milestone payments related collaborative agreements see notes acquisitions collaborations arrangements debt credit facilities leases commitments contingencies income taxes notes consolidated financial statements included item annual report additional information enter certain unconditional purchase obligations capital expenditure projects commitments normal course business changes commitments year would material impact companys ability meet either shortterm longterm cash requirements future capital requirements depend many factors including limited following commercial performance current future products progress scope rd efforts including preclinical studies clinical trials cost timing outcome regulatory reviews expansion sales marketing capabilities possibility acquiring additional manufacturing capabilities office facilities possibility acquiring companies new products debt service requirements future dividends subject declaration board directors establishment additional collaborative relationships companies costs associated defense settlement adverse results government investigations litigation may future require additional funding could form proceeds equity debt financings funding required guarantee available us favorable terms may choose repay certain longterm debt obligations prior maturity dates based assessment current longterm liquidity capital requirements critical accounting estimates see note organization summary significant accounting policies notes consolidated financial statements included item annual report information significant accounting policies estimates involved preparation financial statements believe following reflect critical accounting estimates used preparation consolidated financial statements rebates chargebacks rebates chargebacks determined using complex estimation process subject uncertainty part due lag date product sales date related rebates chargeback claims settled developing estimates rebates chargebacks consider following product sales including product mix pricing historical estimated payer mix statutory discount requirements contractual terms historical claims experience processing time lags estimated patient population known market events trends market research channel inventory data obtained major us wholesalers pertinent internal external information following table summarizes consolidated activities ending balances rebates chargebacks accounts including adjustments made relating previous years sales result changes estimates balance decreaseincrease balance end millions beginning year product sales payments year year ended december activity related sales activity related sales prior total year ended december activity related sales activity related sales prior total net product sales include impact million changes rebate chargeback estimates related sales prior historically actual rebates chargebacks claimed prior periods varied less estimates valuation intangible assets determining fair values intangible assets whether part business combination impairment assessment involves use probability weighted income approach discounts expected future cash flows present value requires use critical estimated inputs including identification product candidates sufficient substance requiring separate recognition estimates projected future cash flows including revenues operating profits related products product candidates example include significant inputs addressable patient population treatment duration projected market share probability technical regulatory success unapproved product candidates considering stages development time resources needed complete development approval product candidates appropriate discount rate based estimated weightedaverage cost capital companies profiles similar profile representing rate market participants would use value intangible assets life potential commercialized products associated risks including inherent difficulties uncertainties developing product candidate obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets estimates subject uncertainty due high rate failure inherent discovery development new products delays occur development approval product launch processes unanticipated decisions made regulatory agencies advent competing products unexpected changes us global financial markets unanticipated events circumstances future events result adverse changes critical assumptions used determining fair value impairment charges intangible assets may recorded could material financial statements example recognized billion impairment charge related hrher iprd intangible asset related expected delay launch timing caused decrease market share assumptions based expected competitive environment legal contingencies party various legal actions certain significant matters described note commitments contingencies notes consolidated financial statements included item annual report critical inputs accruals recorded disclosures provided relation matters include probability certain outcome case determination whether exposure reasonably estimable amount potential exposure inputs subject uncertainty due changes legal facts circumstances case status proceedings applicable law views legal counsel views judges jury involved case upon final resolution matters possible may loss excess amount recorded amounts could material adverse effect results operations cash flows financial position periodically reassess matters additional information becomes available adjust estimates assumptions facts circumstances indicate need changes example fourth quarter recorded accrual billion current liabilities consolidated balance sheets settlement related bictegravir litigation income taxes subject income taxes us various foreign jurisdictions including ireland critical inputs determining provision income taxes related tax balances include forecasts future income expenses potential tax planning strategies determination probability certain tax positions sustained upon examination tax authorities inputs subject uncertainty due potential changes facts circumstances economic political conditions changes existing tax laws new regulations interpretations tax authorities changes conditions could material adverse impact results operations financial position item quantitative qualitative disclosures market risk exposed market risks may result changes foreign currency exchange rates interest rates credit equity prices reduce certain risks enter various types foreign currency derivative hedging transactions follow investment guidelines monitor outstanding receivables part risk management program may also enter transactions interest rate derivative hedges needed foreign currency exchange rate risk operations countries worldwide result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes foreign currency exchange rates us dollar various foreign currencies significant euro us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative value sales increases overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar approximately product sales denominated foreign currencies partially mitigate impact changes currency exchange rates net cash flows foreign currency denominated sales enter foreign currency exchange forward contracts also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid general market risks contracts offset corresponding gains losses transactions hedged december open foreign currency forward contracts notional amounts billion billion respectively hypothetical adverse movement foreign currency exchange rates compared us dollar relative exchange rates december would resulted reduction fair value contracts approximately million million respectively realized would negatively affected earnings remaining life contracts analysis consider impact hypothetical changes foreign currency exchange rates would anticipated transactions foreign currency sensitive instruments designed offset interest rate credit risk portfolio availableforsale debt securities senior unsecured notes create exposure interest rate credit risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based credit rating maturity industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return following table summarizes expected maturities average interest rates interestgenerating assets interestbearing liabilities december expected maturity total fair millions except percentages thereafter total value assets availableforsale debt securities average interest rate liabilities senior unsecured fixed rate notes including current portion average interest rate amounts represent principal balances addition senior unsecured fixed rate notes billion fiveyear revolving credit facility matures june amounts outstanding fiveyear revolving credit facility december see note debt credit facilities notes consolidated financial statements included item annual report additional information equity price risk hold shares common stock certain publicly traded biotechnology companies primarily connection license collaboration agreements equity securities measured fair value changes fair value recognized earnings fair value equity securities approximately billion billion december respectively changes fair value equity securities impacted volatility stock market changes general economic conditions among factors hypothetical increase decrease stock prices equity securities would increased decreased fair value december approximately million million respectively item financial statements supplementary data gilead sciences inc index consolidated financial statements supplementary data years ended december contents report independent registered public accounting firm pcaob id audited consolidated financial statements consolidated balance sheets consolidated statements income consolidated statements comprehensive income loss consolidated statements stockholders equity consolidated statements cash flows notes consolidated financial statements report independent registered public accounting firm stockholders board directors gilead sciences inc opinion financial statements audited accompanying consolidated balance sheets gilead sciences inc company december related consolidated statements income comprehensive income stockholders equity cash flows three years period ended december related notes collectively referred consolidated financial statements opinion consolidated financial statements present fairly material respects financial position company december results operations cash flows three years period ended december conformity us generally accepted accounting principles also audited accordance standards public company accounting oversight board united states pcaob company 's internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework report dated february expressed unqualified opinion thereon basis opinion financial statements responsibility company 's management responsibility express opinion companys financial statements based audits public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement whether due error fraud audits included performing procedures assess risks material misstatement financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation financial statements believe audits provide reasonable basis opinion critical audit matters critical audit matters communicated matters arising current period audit financial statements communicated required communicated audit committee relate accounts disclosures material financial statements involved especially challenging subjective complex judgments communication critical audit matters alter way opinion consolidated financial statements taken whole communicating critical audit matters providing separate opinions critical audit matters accounts disclosures relate government commercial rebates description matter fully described note company estimates reductions revenues amounts payable payers healthcare providers united states various government commercial rebate programs period related sales occur rebates may vary product payer individual payer plans may known point sale estimated reductions revenue based product sales historical expected payer mix discount rates various estimated actual data adjusted current period expectations auditing companys estimated reductions revenue rebates complex involved significant judgment particularly assessing reasonableness estimated payer mix applied sales period estimate relies heavily historical data adjusted changes payer mix expectations time addressed evaluated tested design operating effectiveness companys internal controls managements estimation matter audit review reductions revenue rebate programs including controls assess payer mix assumption also tested completeness accuracy data utilized controls accuracy calculations supporting managements estimates test managements estimation methodology determining payer mix audit procedures included among others analytically evaluating managements estimates evaluating evidence contrary estimated amounts performing sensitivity analysis rates used estimates performing comparison actual payments related amounts accrued current prior years valuation inprocess research development intangible asset description matter company recognized billion impairment charge related inprocess research development iprd intangible asset related trodelvy treatment patients hormone receptorpositive human epidermal growth factor receptor negative hrher breast cancer december intangible asset remaining carrying value billion discussed note intangible assets indefinite useful lives related iprd projects acquired business combination measured respective fair values acquisition date considered indefinitelived completion abandonment associated rd efforts company tests indefinitelived intangible assets impairment annual basis annual tests become aware events changes would indicate fair values assets carrying amounts impairment charge recognized degree carrying value exceeds fair value discussed note company estimated fair value iprd intangible asset related trodelvy patients hrher breast cancer connection interim impairment assessment march annual impairment assessment october auditing fair values iprd intangible asset complex due significant judgment required estimating fair values particular fair value estimates required use valuation methodology sensitive significant assumptions eg discount rate probability technical regulatory success addressable patient population treatment duration projected market share affected expected future market economic conditions addressed evaluated tested design operating effectiveness companys internal controls determination matter audit estimated fair value iprd intangible asset related trodelvy patients hrher breast cancer interim annual impairment assessments example tested controls management 's review valuation methodology significant assumptions used develop fair value estimates also tested management 's controls validate data used fair value estimates complete accurate test estimated fair value asset interim annual assessment dates audit procedures among others included evaluating company 's use appropriate valuation methodology assistance valuation specialist evaluating sensitivity analyses determine assumptions greatest impact fair value determination testing completeness accuracy underlying data audit procedures significant assumptions included comparing assumptions current industry market economic trends historical results company 's business guideline companies within industry relevant factors example evaluated probability technical regulatory success considering phase development clinical projects company 's history obtaining regulatory approval addition evaluated expected addressable patient populations comparing companys estimates external industry forecasts ernst young llp served companys auditor since san jose california february gilead sciences inc consolidated balance sheets december millions except per share amounts assets current assets cash cash equivalents shortterm marketable debt securities accounts receivable net inventories prepaid current assets total current assets property plant equipment net longterm marketable debt securities intangible assets net goodwill longterm assets total assets liabilities stockholders equity current liabilities accounts payable accrued rebates current liabilities current portion longterm debt obligations net total current liabilities longterm debt net longterm income taxes payable deferred tax liability longterm obligations commitments contingencies note stockholders equity preferred stock par value per share shares authorized none outstanding common stock par value per share authorized shares issued outstanding respectively additional paidin capital accumulated comprehensive income retained earnings total gilead stockholders equity noncontrolling interest total stockholders equity total liabilities stockholders equity see accompanying notes gilead sciences inc consolidated statements income year ended december millions except per share amounts revenues product sales royalty contract revenues total revenues costs expenses cost goods sold research development expenses acquired inprocess research development expenses inprocess research development impairment selling general administrative expenses total costs expenses operating income interest expense income expense net income income taxes income tax expense net income net loss attributable noncontrolling interest net income attributable gilead basic earnings per share attributable gilead shares used basic earnings per share attributable gilead calculation diluted earnings per share attributable gilead shares used diluted earnings per share attributable gilead calculation see accompanying notes gilead sciences inc consolidated statements comprehensive income loss year ended december millions net income comprehensive income loss net foreign currency translation loss availableforsale debt securities net unrealized gain loss net tax impact respectively reclassifications net income net tax impact respectively net change cash flow hedges net unrealized gain loss net tax impact respectively reclassifications net income net tax impact respectively net change comprehensive income loss comprehensive income loss comprehensive loss attributable noncontrolling interest comprehensive income loss attributable gilead see accompanying notes gilead sciences inc consolidated statements stockholders equity gilead stockholders equity accumulated common stock additional total paidin comprehensive retained noncontrolling stockholders millions except per share amounts shares amount capital income loss earnings interest equity balance december cumulative effect adoption new accounting standard change noncontrolling interest net income loss comprehensive income loss net tax issuances employee stock purchase plan issuances equity incentive plans stockbased compensation repurchases common stock dividends declared per share balance december net income loss comprehensive income net tax issuances employee stock purchase plan issuances equity incentive plans stockbased compensation repurchases common stock dividends declared per share balance december net income loss comprehensive loss net tax issuances employee stock purchase plan issuances equity incentive plans stockbased compensation repurchases common stock dividends declared per share balance december see accompanying notes gilead sciences inc consolidated statements cash flows year ended december millions operating activities net income adjustments reconcile net income net cash provided operating activities depreciation expense amortization expense stockbased compensation expense deferred income taxes net loss equity securities acquired inprocess research development expenses inprocess research development impairment changes operating assets liabilities accounts receivable net inventories prepaid expenses accounts payable income taxes payable accrued liabilities net cash provided operating activities investing activities purchases marketable debt securities proceeds sales marketable debt securities proceeds maturities marketable debt securities acquisitions including inprocess research development net cash acquired purchases equity securities capital expenditures net cash used investing activities financing activities proceeds debt financing net issuance costs proceeds issuances common stock repurchases common stock repayments debt obligations payment dividends net cash provided used financing activities effect exchange rate changes cash cash equivalents net change cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period supplemental disclosure cash flow information interest paid net amounts capitalized income taxes paid see accompanying notes gilead sciences inc notes consolidated financial statements organization summary significant accounting policies organization gilead sciences inc gilead us biopharmaceutical company pursued achieved breakthroughs medicine three decades goal creating healthier world people committed advancing innovative medicines prevent treat lifethreatening diseases including hiv viral hepatitis cancer operate countries worldwide headquarters foster city california portfolio marketed products includes ambisome atripla biktarvy cayston complera descovy descovy prep emtriva epclusa eviplera genvoya harvoni hepcludex hepsera jyseleca letairis odefsey ranexa sovaldi stribild sunlenca tecartus trodelvy truvada truvada prep tybost veklury vemlidy viread vosevi yescarta zydelig approval status hepcludex jyseleca vary worldwide hepcludex jyseleca approved us also sell distribute authorized generic versions epclusa harvoni us separate subsidiary asegua therapeutics llc addition sell distribute certain products corporate partners collaborative agreements one operating segment primarily focuses discovery development commercialization innovative medicines areas unmet medical need chief executive officer chief operating decisionmaker codm manages allocates resources operations company entitywide basis managing allocating resources entitywide basis enables codm assess overall level resources available best deploy resources across functions research development rd projects based unmet medical need scientific data probability technical regulatory successful development market potential considerations necessary reallocate resources among internal rd portfolio external opportunities best support longterm growth business see note revenues summary disaggregated revenues product geographic region summary significant accounting policies basis presentation accompanying consolidated financial statements prepared accordance us generally accepted accounting principles include accounts gilead whollyowned subsidiaries certain variable interest entities vies primary beneficiary intercompany transactions eliminated consolidated entities exposed less economics record net income loss attributable noncontrolling interests consolidated statements income equal percentage economic ownership interest retained entities respective noncontrolling parties obtain variable interest another entity assess inception relationship upon occurrence certain significant events whether entity vie whether primary beneficiary vie based power direct activities vie significantly impact vies economic performance obligation absorb losses right receive benefits vie could potentially significant vie preparation consolidated financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate significant accounting policies estimates base estimates historical experience various marketspecific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources estimates assessed period updated reflect current information actual results may differ significantly estimates certain amounts percentages herein may sum recalculate due rounding beginning second quarter expenses related development milestones collaboration payments made prior regulatory approval developed product reclassified research development expenses acquired inprocess research development expenses consolidated statements income concurrently reclassified cash payments related expenses acquisitions including inprocess research development net cash acquired within investing activities consolidated statements cash flows believe presentation assists users financial statements better understand total costs incurred acquire inprocess research development iprd projects prior periods revised reflect classification resulting reduction previouslyreported research development expenses million million years ended december respectively revenue recognition product sales recognize revenue product sales control product transfers customer generally upon shipment delivery certain cases upon corresponding sales customer third party revenues recognized net estimated rebates chargebacks cash discounts prompt payment distributor fees sales return provisions related deductions deductions product sales referred grosstonet deductions estimated recorded period related product sales occur payment terms customers generally range days however payment terms differ jurisdiction customer instances type product revenues product sales net grosstonet deductions recorded extent significant reversal amount cumulative revenue recognized probable occurring uncertainty associated grosstonet deductions subsequently resolved taxes assessed governmental authorities collected customers excluded product sales expect contract inception period transfer control corresponding payment customer one year less adjust amount consideration effects financing component shipping handling activities considered fulfillment activities separate performance obligation grosstonet deductions rebates chargebacks rebates chargebacks based contractual arrangements statutory requirements include amounts due payers healthcare providers various programs amounts may vary product payer individual plans providers qualified certain programs purchase products wholesalers distributors discount wholesalers distributors charge discount back us rebates chargebacks estimated primarily based product sales including product mix pricing historical estimated payer mix discount rates among inputs require significant estimates judgment assess update estimates reporting period reflect actual claims current information chargebacks payable direct customers generally classified reductions accounts receivable consolidated balance sheets rebates payable third party payers healthcare providers recorded accrued rebates consolidated balance sheets cash discounts estimate cash discounts based contractual terms historical customer payment patterns expectations regarding future customer payment patterns distributor fees inventory management agreements significant us wholesalers pay wholesalers fee primarily compliance certain contractuallydetermined covenants maintenance agreedupon inventory levels distributor fees based contractuallydetermined fixed percentage sales allowance sales returns allowances made estimated sales returns customers recorded period related revenue recognized typically permit returns product damaged defective otherwise used customer us typically permit returns six months prior one year product expiration date outside us returns allowed certain countries limited basis estimates sales returns based primarily analysis historical product return patterns industry information reporting return rates similar products contractual agreement terms also take consideration known expected changes marketplace specific product royalty contract revenues royalty revenue recognized period obligation satisfied corresponding sales corporate partners occur contract revenues recognized performance obligation satisfied research development expenses research development expenses recorded incurred consist primarily clinical studies performed contract research organizations cros materials supplies expense reimbursements collaboration partners personnel costs including salaries benefits stockbased compensation expense overhead allocations consisting various support infrastructure costs time time enter development collaboration agreements share expenses collaborative partner record payments received collaborative partners share development costs reduction research development expenses clinical study costs significant component research development expenses clinical studies performed thirdparty cros monitor levels performance significant contract including extent patient enrollment activities communications cros accrue costs clinical studies performed cros service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cros material cro contracts terminable us upon written notice generally liable actual services completed cro certain noncancelable expenses incurred point termination payments make rd services prior services rendered recorded prepaid assets within prepaid current assets consolidated balance sheets expensed services provided acquired inprocess research development expenses acquired inprocess research development expenses recorded incurred reflect costs externallydeveloped iprd projects acquired directly transaction business combination alternative future use including upfront milestone payments related various collaborations costs rights iprd projects selling general administrative expenses selling general administrative expenses recorded incurred consist primarily personnel costs facilities overhead costs outside marketing advertising legal expenses general administrative costs related sales marketing finance human resources legal administrative activities advertising expenses within selling general administrative expenses including promotional expenses recorded incurred million million million years ended december respectively stockbased compensation provide stockbased compensation form various types equitybased awards including restricted stock units rsus performance share units psus stock options employee stock purchase plan international employee stock purchase plan together amended espp stockbased compensation expense based estimated fair value award grant date first date espp purchase period recognized requisite service periods consolidated statements income using straightline expense attribution approach reduced estimated forfeitures estimate forfeitures based historical experience requisite service period could shorter vesting period employee retirement eligible employee terminates due death disability estimated fair value rsus based closing price common stock grant date psus depending terms award fair value date grant determined based either monte carlo valuation methodology closing stock price date grant stock option espp awards estimated fair value based blackscholes option valuation model estimated inputs model include expected volatility based blend historical volatility common stock price along implied volatility traded options common stock ii expected term years based weightedaverage period awards expected remain outstanding using historical cancellation exercise data contractual terms vesting terms award iii riskfree interest rate based observed interest rates appropriate term stockbased awards iv expected dividend yield based history expectation dividend payments earnings per share basic earnings per share attributable gilead calculated based net income attributable gilead consolidated statements income divided weightedaverage number shares common stock outstanding period diluted earnings per share attributable gilead calculated based net income attributable gilead consolidated statements income divided weightedaverage number shares common stock dilutive securities outstanding period potentially dilutive shares common stock resulting assumed exercise outstanding stock options equivalents determined treasury stock method cash cash equivalents consider highly liquid investments insignificant interest rate risk original maturity three months less purchase date cash equivalents marketable debt securities marketable debt securities classified availableforsale carried estimated fair values determine appropriate classification marketable debt securities time purchase reevaluate designation balance sheet date unrealized gains losses availableforsale debt securities reported accumulated comprehensive income consolidated balance sheets realized point reclassified income expense net consolidated statements income interest amortization purchase premiums discounts expected credit losses also recorded income expense net consolidated statements income cost securities sold based specific identification method regularly review investments declines fair value amortized cost basis determine whether impairment due creditrelated factors noncreditrelated factors review includes creditworthiness security issuers severity unrealized losses whether intent sell securities whether likely required sell securities recovery amortized cost bases determine portion unrealized loss due expected credit loss recognize loss amount income expense net corresponding allowance carrying value security hold portion unrealized loss related factors credit losses recognized accumulated comprehensive income accounts receivable trade accounts receivable recorded net allowances wholesaler chargebacks related government programs cash discounts prompt payment estimated credit losses estimates allowance credit losses consider number factors including existing contractual payment terms individual customer circumstances historical payment patterns customers review local economic environment potential impact expected future customer payment patterns government funding reimbursement practices inventories inventories recorded lower cost net realizable value cost determined firstin firstout basis periodically review inventories identify obsolete slowmoving excess otherwise unsaleable items obsolete slowmoving excess unsaleable items observed alternate uses inventory record writedown net realizable value charge cost goods sold consolidated statements income determination net realizable value requires judgment including consideration many factors estimates future product demand product net selling prices current future market conditions potential product obsolescence among others future commercialization considered probable future economic benefit expected realized based managements judgment capitalize prelaunch inventory costs prior regulatory approval number factors considered including current status regulatory approval process potential impediments approval process safety efficacy anticipated rd initiatives could impact indication compound used viability commercialization marketplace trends equity securities equity securities readily determinable fair values including elected fair value option recorded fair market value unrealized gains losses included income expense net consolidated statements income equity securities without readily determinable fair values recorded using measurement alternative cost less impairment adjusted observable price changes orderly transactions identical similar investments issuer impairments adjustments recorded income expense net consolidated statements income investments entities significant influence meet requirements consolidation elected fair value option use equity method accounting share underlying income loss entities reported income expense net consolidated statements income investments equity securities classified prepaid current assets longterm assets consolidated balance sheets generally depending marketability whether securities subject lockup provisions regularly review securities indicators impairment property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straightline method repairs maintenance costs expensed incurred estimated useful lives years generally follows description estimated useful life buildings improvements shorter years useful life laboratory manufacturing equipment office computer equipment leasehold improvements shorter useful life lease term see impairment longlived assets additional information leases determine arrangement contains lease inception classify lease operating financing rightofuse assets lease liabilities recognized commencement date based present value lease payments lease term noncancelable period stated contract adjusted options extend terminate reasonably certain exercise option rightofuse assets adjusted prepaid lease payments lease incentives initial direct costs incurred operating lease expense minimum lease payments recognized straightline basis lease term account lease nonlease components lease agreements single lease component determining lease assets liabilities addition recognize rightofuse assets liabilities leases lease terms one year less operating leases provide implicit interest rate generally utilize collateralized incremental borrowing rate applied portfolio approach relevant based information available commencement date determine lease liability acquisitions including goodwill intangible assets contingent consideration account business combinations using acquisition method accounting generally requires assets acquired including iprd projects liabilities assumed recorded fair values acquisition date consolidated balance sheets excess consideration fair value net assets acquired recorded goodwill determination estimated fair value requires us make significant estimates assumptions result may record adjustments fair values assets acquired liabilities assumed within measurement period may one year acquisition date corresponding offset goodwill transaction costs associated business combinations expensed incurred intangible assets related iprd projects considered indefinitelived abandonment completion associated rd efforts generally occurs regulatory approval obtained goodwill indefinitelived intangible assets amortized instead tested impairment annually frequently events changes circumstances indicate likely assets impaired intangible assets finite useful lives amortized estimated useful lives primarily straightline basis also periodically reviewed changes facts circumstances resulting reduction estimated useful life asset requiring acceleration amortization see impairment long lived assets additional information determining initial fair value intangible asset quantitative analysis required determine impairment use probabilityweighted income approach discounts expected future cash flows present value using discount rate based estimated weightedaverage cost capital companies profiles similar represents rate market participants would use value intangible assets cash flow models require use level fair value measurements inputs including estimated revenues example include significant inputs addressable patient population treatment duration projected market share assessment assets life cycle competitive trends impacting asset costs probability technical regulatory success among factors connection certain acquisitions may required pay future consideration contingent upon achievement specified development regulatory approval salesbased milestone events record contingent consideration resulting business combination fair value acquisition date reporting period thereafter revalue obligations record increases decreases fair value consolidated statements income time payment made increases decreases fair value contingent consideration liabilities result updates assumptions expected timing probability achieving specified milestones changes projected revenues changes discount rates determine net assets acquired meet definition business combination acquisition method accounting transaction accounted asset acquisition therefore goodwill recorded contingent consideration generally recognized acquisition date asset acquisition upfront payments allocated iprd projects acquisition date subsequent milestone payments expensed incurred consolidated statements income unless alternative future use impairment longlived assets longlived assets including property plant equipment finitelived intangible assets reviewed impairment whenever facts circumstances either internally externally may indicate carrying value asset may recoverable indication impairment test recoverability comparing estimated undiscounted future cash flows expected result use asset useful life carrying amount asset asset group asset asset group determined impaired excess carrying value asset asset group estimated fair value recognized impairment loss derivatives recognize derivative instruments either assets liabilities fair value consolidated balance sheets unrealized changes fair value derivatives designated part hedge transaction recorded accumulated comprehensive income hedges related forecasted product sales unrealized gains losses accumulated comprehensive income reclassified product sales consolidated statements income respective hedged transactions affect earnings changes fair value derivatives part hedge transaction recorded period income expense net consolidated statements income using regression analysis assess inception ongoing basis whether derivatives used hedging transactions effective offsetting changes cash flows fair values hedged items determine forecasted transaction probable occurring discontinue hedge accounting affected portion hedge instrument related unrealized gain loss contract recognized income expense net consolidated statements income contingencies recognize accruals loss contingencies extent conclude loss probable reasonably estimable accrue best estimate loss within range however estimate range better accrue minimum amount range determine material loss reasonably possible disclose possible loss range loss amount loss estimated time income taxes income tax provision computed liability method significant estimates required determining provision income taxes estimates based interpretations applicable tax laws regulations deferred tax assets liabilities determined based difference financial statement tax basis assets liabilities using enacted tax rates effect year differences expected reverse record valuation allowance reduce deferred tax assets amounts likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance expect realize deferred tax assets previously recorded valuation allowance reduce valuation allowance period determination first made recognize tax benefit uncertain tax position likely tax position sustained upon examination tax authorities based technical merits position tax benefit recognized consolidated financial statements particular tax position based largest benefit likely realized amount unrecognized tax benefits utb adjusted appropriate changes facts circumstances significant amendments existing tax law new regulations interpretations tax authorities new information obtained tax examination resolution examination recognize accrued interest penalties appropriate related utb income tax expense consolidated statements income elected account tax global intangible lowtaxed income enacted part tax cuts jobs act component tax expense period tax incurred foreign currency translation transactions consolidated financial statements presented us dollars functional currency foreign subsidiaries local currency revenues expenses gains losses nonus dollar functional currency entities translated us dollars using average currency exchange rates period assets liabilities entities translated using exchange rates approximate rate balance sheet date foreign currency translation adjustments recorded component accumulated comprehensive income consolidated balance sheets foreign currency transaction gains losses transactions denominated functional currency recorded income expense net consolidated statements income fair value measurements apply fair value accounting financial nonfinancial assets liabilities recognized disclosed fair value financial statements recurring basis define fair value price would received selling asset paid transfer liability orderly transaction market participants measurement date determining fair value measurements assets liabilities required recorded fair value consider principal advantageous market would transact marketbased risk measurements assumptions market participants would use pricing asset liability risks inherent valuation techniques transfer restrictions credit risks determine fair value using fair value hierarchy establishes three levels inputs may used measure fair value follows level inputs include quoted prices active markets identical assets liabilities level inputs include observable inputs level inputs quoted prices similar assets liabilities active markets quoted prices identical similar assets liabilities markets active inputs observable corroborated observable market data substantially full term asset liability level inputs include unobservable inputs supported little market activity significant fair value underlying asset liability level assets liabilities include whose fair value measurements determined using pricing models discounted cash flow methodologies similar valuation techniques significant management judgment estimation revenues disaggregation revenues following table summarizes total revenues year ended december year ended december year ended december millions us europe international total us europe international total us europe international total product sales hiv biktarvy compleraeviplera descovy genvoya odefsey stribild truvada revenue share symtuza hiv total hiv veklury hepatitis c virus hcv ledipasvir sofosbuvir sofosbuvirvelpatasvir hcv total hcv hepatitis b virus hbv hepatitis delta virus hdv vemlidy viread hbvhdv total hbvhdv cell therapy tecartus yescarta total cell therapy trodelvy ambisome letairis total total product sales royalty contract revenues total revenues represents revenue cobicistat c emtricitabine ftc tenofovir alafenamide taf symtuza darunavircftctaf fixed dose combination product commercialized janssen sciences ireland unlimited company janssen see note collaborations arrangements additional information includes atripla emtriva sunlenca tybost amounts consist sales harvoni authorized generic version harvoni sold separate subsidiary asegua therapeutics llc amounts consist sales epclusa authorized generic version epclusa sold separate subsidiary asegua therapeutics llc includes vosevi sovaldi includes hepcludex hepsera includes cayston jyseleca ranexa zydelig revenues major customers following table summarizes revenues customers individually accounted total revenues year ended december percentage total revenues amerisourcebergen corporation cardinal health inc mckesson corporation revenues recognized performance obligations satisfied prior periods following table summarizes revenues recognized performance obligations satisfied prior periods year ended december millions revenue share janssen royalties licenses intellectual property changes estimates see note collaborations arrangements additional information contract balances contract assets consist unbilled amounts primarily arrangements licensing intellectual property predominant performance obligation totaled million million december respectively contract liabilities generally result receipt advance payment performance contract million million december respectively fair value measurements following table summarizes types assets liabilities measured fair value recurring basis level within fair value hierarchy december december millions level level level total level level level total assets availableforsale debt securities us treasury securities us government agencies securities nonus government securities certificates deposit corporate debt securities residential mortgage assetbacked securities equity securities money market funds equity investment galapagos nv galapagos equity investment arcus biosciences inc arcus publicly traded equity securities deferred compensation plan foreign currency derivative contracts total liabilities liability myr gmbh myr contingent consideration deferred compensation plan foreign currency derivative contracts total see note collaborations arrangements additional information level inputs availableforsale debt securities availableforsale debt securities estimate fair values reviewing trading activity pricing measurement date taking consideration valuations obtained thirdparty pricing services pricing services utilize industry standard valuation models including incomebased marketbased approaches significant inputs observable either directly indirectly estimate fair value inputs include reported trades brokerdealer quotes similar securities issuer credit spreads benchmark securities prepaymentdefault projections based historical data observable inputs foreign currency derivative contracts substantially foreign currency derivative contracts maturities within month time horizon counterparties minimum credit rating equivalent sp global ratings moodys investors service inc fitch ratings inc estimate fair values contracts taking consideration valuations obtained thirdparty valuation service utilizes incomebased industry standard valuation model significant inputs observable either directly indirectly inputs include foreign currency exchange rates secured overnight financing rate swap rates inputs applicable observable commonly quoted intervals senior unsecured notes total estimated fair values senior unsecured notes determined using level inputs based quoted market values approximately billion billion december respectively carrying values billion billion december respectively level inputs contingent consideration connection first quarter acquisition myr recorded liability contingent consideration revalued reporting period related contingency resolved contingent consideration estimated using probabilityweighted scenarios us food drug administration fda approval hepcludex following table summarizes change fair value contingent consideration year ended december millions beginning balance additions changes valuation assumptions effect foreign exchange remeasurement ending balance included research development expenses consolidated statements income primarily related increasing discount rates updated probability rate estimates included income expense net consolidated statements income liability related future royalties recorded liability related future royalties part fourth quarter acquisition immunomedics inc immunomedics subsequently amortized using effective interest method remaining estimated life fair values liability related future royalties billion billion december respectively carrying value billion december see note debt credit facilities additional information nonrecurring fair value measurements recorded partial impairment charge billion related certain iprd assets see note goodwill intangible assets additional information indicators impairment noted fair value level transfers transfers level level level periods presented availableforsale debt securities equity securities availableforsale debt securities following table summarizes availableforsale debt securities december december gross gross gross gross amortized unrealized unrealized estimated amortized unrealized unrealized estimated millions cost gains losses fair value cost gains losses fair value us treasury securities us government agencies securities nonus government securities certificates deposit corporate debt securities residential mortgage assetbacked securities total following table summarizes information related availableforsale debt securities continuous unrealized loss position classified length time december less months months longer total gross gross gross unrealized estimated unrealized estimated fair unrealized estimated millions losses fair value losses value losses fair value us treasury securities us government agencies securities nonus government securities certificates deposit corporate debt securities residential mortgage assetbacked securities total december less months months longer total gross gross gross unrealized estimated unrealized estimated fair unrealized estimated millions losses fair value losses value losses fair value us treasury securities us government agencies securities nonus government securities certificates deposit corporate debt securities residential mortgage assetbacked securities total allowance credit losses recognized investments unrealized losses december currently intend sell likely required sell investments recovery amortized cost bases unrealized losses primarily driven broader change interest rates adverse conditions identified would prevent issuer making scheduled principal interest payments following table summarizes classification availableforsale debt securities consolidated balance sheets millions december december cash cash equivalents shortterm marketable debt securities longterm marketable debt securities total following table summarizes availableforsale debt securities contractual maturity december millions amortized cost fair value within one year one year five years five years ten years ten years total equity securities equity securities measured fair value following table summarizes classification equity securities measured fair value recurring basis consolidated balance sheets millions december december cash cash equivalents prepaid current assets longterm assets total prepaid current assets longterm assets include equity method investments arcus galapagos respectively elected applied fair value option believe best reflects underlying economics investments investment galapagos classified longterm assets due certain lockup provisions amended subscription agreement extend august equity securities equity method investments equity investments without readily determinable fair values million million december respectively excluded table amounts included longterm assets consolidated balance sheets unrealized gains losses net unrealized losses recognized equity securities million million billion years ended december respectively included income expense net consolidated statements income related party transaction years ended december gilead donated certain equity securities fair value gilead foundation california nonprofit public benefit corporation foundation foundation related party certain officers also serve directors foundation donation expense million million recorded within selling general administrative expenses consolidated statements income years ended december respectively derivative financial instruments operations foreign countries expose us market risk associated foreign currency exchange rate fluctuations us dollar various foreign currencies primarily euro manage risk hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions seek limit risk counterparties contracts may unable perform also seek limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrealized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes derivative instruments use hedge exposures certain monetary assets liabilities denominated nonfunctional currency designated hedges derivative instruments use hedge exposures forecasted product sales designated cash flow hedges maturities months less december held foreign currency exchange contracts outstanding notional amounts billion billion respectively derivative contracts allow us right offset assets liabilities presented amounts consolidated balance sheets gross basis following table summarizes classification fair values derivative instruments including potential effect offsetting december derivative assets derivative liabilities millions classification fair value classification fair value derivatives designated hedges foreign currency exchange contracts prepaid current assets current liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts prepaid current assets current liabilities total derivatives designated hedges total derivatives presented gross consolidated balance sheets gross amounts offset consolidated balance sheets derivative financial instruments cash collateral received pledged net amount legal offset december derivative assets derivative liabilities millions classification fair value classification fair value derivatives designated hedges foreign currency exchange contracts prepaid current assets current liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts prepaid current assets current liabilities total derivatives designated hedges total derivatives presented gross consolidated balance sheets gross amounts offset consolidated balance sheets derivative financial instruments cash collateral received pledged net amount legal offset following table summarizes effect derivative contracts consolidated financial statements year ended december millions derivatives designated hedges gain loss recognized accumulated comprehensive income gain loss reclassified accumulated comprehensive income product sales derivatives designated hedges gain loss recognized income expense net majority gains losses related hedged forecasted transactions reported accumulated comprehensive income december expected reclassified product sales within months discontinuances cash flow hedges years presented cash flow effects derivative contracts years ended december included within net cash provided operating activities consolidated statements cash flows acquisitions mirobio september acquired outstanding share capital mirobio ltd mirobio privatelyheld ukbased biotechnology company focused restoring immune balance agonists targeting immune inhibitory receptors million cash result mirobio became whollyowned subsidiary accounted transaction asset acquisition recorded million charge acquired inprocess research development expenses consolidated statements income remaining purchase price relates various assets acquired liabilities assumed myr first quarter completed acquisition myr german biotechnology company myr focuses development commercialization therapeutics treatment hdv acquisition provided gilead hepcludex conditionally approved european medicines agency ema july treatment chronic hdv infection adults compensated liver disease upon closing myr became whollyowned subsidiary gilead financial results myr included consolidated financial statements date acquisition aggregate consideration acquisition billion billion primarily consisted billion billion paid upon closing contingent consideration million subject customary adjustments representing potential future milestone payment upon fda approval hepcludex fair value contingent liability estimated using probabilityweighted scenarios fda approval million acquisition date december fair value liability million included current liabilities consolidated balance sheets december fair value liability million included longterm obligations see note fair value measurements additional information acquisition myr accounted business combination using acquisition method accounting following table summarizes estimated fair values assets acquired liabilities assumed acquisition date millions amount intangible assets finitelived intangible asset acquired iprd deferred income taxes net assets liabilities net total identifiable net assets goodwill total consideration intangible assets finitelived intangible asset million represents estimated fair value hepcludex hdv europe acquisition date fair value determined applying income approach using unobservable inputs estimate probabilityweighted net cash flows attributable hepcludex hdv europe discount rate discount rate used represents estimated rate market participants would use value intangible asset intangible asset amortized estimated useful life years acquired iprd consists hepcludex hdv regions without regulatory approval including united states estimated aggregate fair value billion acquisition date determined applying income approach using unobservable inputs level fair value measurement disclosure guidance estimate probabilityweighted net cash flows attributable asset discount rate discount rate used represents estimated rate market participants would use value intangible asset deferred income taxes net deferred tax liability based upon difference estimated financial statement basis tax basis net assets acquired estimate final preacquisition net operating losses myr goodwill excess consideration transferred fair values assets acquired liabilities assumed million recorded goodwill primarily reflects future economic benefits arising assets acquired could individually identified separately recognized goodwill recognized myr expected deductible income tax purposes oneyear measurement period completed first quarter adjustments recorded fair values assets acquired liabilities assumed million see note goodwill intangible assets additional information immunomedics fourth quarter completed acquisition immunomedics company focused development antibodydrug conjugate technology cash consideration billion upon closing immunomedics became whollyowned subsidiary gilead acquisition financed majority proceeds september senior unsecured notes offering additional billion borrowing new senior unsecured term loan facility cash hand repaid borrowing senior unsecured term loan facility recorded sharebased compensation expense million related cash settlement accelerated sharebased compensation expense attributable postcombination period primarily recorded selling general administrative expenses research development expenses consolidated statements income year ended december also recorded acquisitionrelated expenses million primarily representing closing costs related fees selling general administrative expenses consolidated statements income year ended december acquisition immunomedics accounted business combination using acquisition method accounting following table summarizes fair values assets acquired liabilities assumed acquisition date millions amount cash cash equivalents inventories intangible assets finitelived intangible asset acquired iprd outlicense contract deferred tax liabilities liability related future royalties assets liabilities net total identifiable net assets goodwill total consideration transferred inventories fair value stepup adjustment million included inventories million acquisition date primarily determined estimated selling price finished inventory less cost complete manufacturing process selling effort stepup adjustment recorded cost goods sold consolidated statements income inventory sold customers research development expenses consolidated statements income inventory used clinical purposes intangible assets finitelived intangible asset billion represents estimated fair value trodelvy metastatic triplenegative breast cancer tnbc acquisition date fair value determined applying income approach using unobservable inputs estimate probabilityweighted net cash flows attributable trodelvy metastatic tnbc discount rate discount rate used represents estimated rate market participants would use value intangible asset intangible asset amortized estimated useful life years acquired iprd assets consist trodelvy hormone receptorpositive human epidermal growth factor receptor negative hrher breast cancer trodelvy nonsmall cell lung cancer trodelvy urothelial cancer uc estimated aggregate fair value billion acquisition date determined applying income approach using unobservable inputs level fair value measurement disclosure guidance estimate probability weighted net cash flows attributable assets discount rate discount rate used represents estimated rate market participants would use value intangible assets trodelvy uc granted accelerated approval fda april billion reclassified finitelived intangibles iprd trodelvy hrher breast cancer partially impaired first quarter subsequently granted approval fda february billion reclassified finitelived intangibles iprd first quarter see note goodwill intangible assets additional information also recorded intangible asset related license supply agreement everest medicines everest entered immunomedics prior acquisition agreement everest granted exclusive license develop commercialize trodelvy certain territories asia make certain sales milestones royalty payments us acquisition date fair value million determined estimating probabilityweighted net cash flows attributable outlicense discount rate discount rate represents estimated rate market participants would use value intangible asset intangible asset amortized estimated useful life years straightline basis reacquired rights everest fourth quarter see note collaborations arrangements additional information deferred income taxes net deferred tax liability based upon difference estimated financial statement basis tax basis net assets acquired estimate final preacquisition net operating losses immunomedics liability related future royalties assumed liability related funding arrangement originally entered immunomedics rpi finance trust rpi prior acquisition immunomedics funding agreement rpi right receive certain royalty amounts subject certain reductions based net sales trodelvy calendar quarter term agreement approximately acquisition date fair value liability estimated billion primarily determined based current estimates future royalty payments rpi life arrangement using real options method effective annual interest rate inputs used valuation liability unobservable considered level fair value measurement disclosure guidance liability related future royalties categorized debt primarily included longterm debt net consolidated balance sheets see notes fair value measurements debt credit facilities additional information goodwill excess consideration transferred fair values assets acquired liabilities assumed billion recorded goodwill primarily reflects future economic benefits arising assets acquired could individually identified separately recognized goodwill recognized immunomedics expected deductible income tax purposes forty seven inc forty seven second quarter completed acquisition forty seven clinicalstage immunooncology company focused developing therapies targeting cancer immune evasion pathways specific cell targeting approaches total consideration billion net acquired cash upon closing forty seven became whollyowned subsidiary gilead accounted transaction asset acquisition since lead asset magrolimab represented substantially fair value gross assets acquired year ended december recorded billion charge representing acquired iprd asset alternative future use acquired inprocess research development expenses stockbased compensation expense million primarily research development expenses consolidated statements income property plant equipment following table summarizes property plant equipment net december millions land land improvements buildings improvements including leasehold improvements laboratory manufacturing equipment office computer equipment construction progress subtotal less accumulated depreciation amortization total includes million million unamortized capitalized software costs december respectively net book value property plant equipment us billion billion december respectively corresponding amount international locations million million december respectively individual international locations accounted less total balances goodwill intangible assets goodwill following table summarizes changes carrying amount goodwill december millions beginning balance goodwill resulting acquisitions measurement period adjustments ending balance goodwill decreased million result finalizing amount acquired net operating losses myr resulted decrease net deferred tax liability acquired december accumulated goodwill impairment losses intangible assets following table summarizes intangible assets net december december gross foreign currency gross foreign currency carrying accumulated translation net carrying carrying accumulated translation net carrying millions amount amortization adjustment amount amount amortization adjustment amount finitelived assets intangible asset sofosbuvir intangible asset axicabtagene ciloleucel intangible asset trodelvy intangible asset hepcludex total finitelived assets indefinitelived assets iprd total intangible assets february fda granted approval trodelvy use adult patients unresectable locally advanced metastatic hrher breast cancer received endocrine based therapy least two additional systemic therapies metastatic setting accordingly related iprd intangible asset billion reclassified finitelived assets first quarter amortization expense aggregate amortization expense related finitelived intangible assets billion billion billion years ended december respectively primarily included cost goods sold consolidated statements income following table summarizes estimated future amortization expense associated finitelived intangible assets december millions amount thereafter total impairment assessments indicators impairment noted years ended december except described iprd impairment weightedaverage discount rates used quantitative assessments iprd intangible assets years assessment described respectively iprd impairment connection acquisition immunomedics allocated portion purchase price acquired iprd intangible assets approximately billion assigned iprd intangible assets related trodelvy treatment patients hrher breast cancer march received data phase tropics study evaluating trodelvy patients hrher metastatic breast cancer received prior endocrine therapy cyclin dependent kinase inhibitors two four lines chemotherapy thirdline plus patients based evaluation study results connection preparation financial statements first quarter updated estimate fair value hrher iprd intangible asset billion march estimate fair value used probabilityweighted income approach discounts expected future cash flows present value requires use level fair value measurements inputs including estimated revenues costs probability technical regulatory success expected cash flows included cash flows hrher metastatic breast cancer thirdline plus patients patients earlier lines therapy subject separate clinical studies revised discounted cash flows lower primarily due delay launch timing thirdline plus patients caused decrease market share assumptions based expected competitive environment march changes plans assumptions related estimated cash flows patients earlier lines therapy used discount rate based estimated weightedaverage cost capital companies profiles similar represents rate market participants would use value intangible assets determined revised estimated fair value carrying value asset result recognized partial impairment charge billion inprocess research development impairment consolidated statements income three months ended march financial information accounts receivable net following table summarizes accounts receivable net december millions accounts receivable less allowances chargebacks less allowances cash discounts less allowances credit losses accounts receivable net majority trade accounts receivable arises product sales us europe inventories following table summarizes inventories december millions raw materials work process finished goods total reported inventories longterm assets total amounts primarily consist raw materials total inventories december included million fair value adjustments resulting immunomedics acquisition fair value adjustments total inventories december current liabilities following table summarizes components current liabilities december millions compensation employee benefits income taxes payable allowance sales returns accrual settlement related bictegravir litigation accrued liabilities current liabilities see note commitments contingencies additional information collaborations arrangements enter licensing strategic collaborations similar arrangements third parties development commercialization certain products product candidates arrangements may involve two parties active participants operating activities collaboration exposed significant risks rewards depending commercial success activities arrangements may include nonrefundable upfront payments expense reimbursements payments us options acquire certain rights contingent obligations us potential development regulatory milestone payments andor salesbased milestone payments royalty payments revenue profitsharing arrangements costsharing arrangements equity investments financial terms arrangements may required make payments upon achievement various developmental regulatory commercial milestones could significant future milestone payments reflected consolidated statements income corresponding events become probable connection regulatory approvals milestone payments made capitalized intangible assets amortized cost goods sold terms collaboration arrangements addition may required pay significant royalties future sales products related arrangements commercialized payment amounts however contingent upon occurrence various future events high degree uncertainty dragonfly april entered strategic research collaboration agreement dragonfly collaboration agreement dragonfly therapeutics inc dragonfly develop natural killer nk cell engagerbased immunotherapies oncology inflammation indications terms dragonfly collaboration agreement received exclusive worldwide license dragonfly ttargeting investigational immunotherapy program df well options completion certain preclinical activities license exclusive worldwide rights develop commercialize additional nk cell engager programs using dragonfly trispecific nk engager platform upon closing dragonfly collaboration agreement made million upfront payment dragonfly made additional million payment related target selection connection august amendment agreement recorded acquired inprocess research development expenses consolidated statements income year ended december payments classified acquisitions including inprocess research development net cash acquired investing activities consolidated statements cash flows year ended december addition dragonfly eligible receive performancebased development regulatory milestone payments million related df program commercial milestone payments royalties worldwide net sales successful exercise options additional nk cell engager programs dragonfly would eligible receive optin payments performancebased development regulatory commercial milestone payments royalties worldwide net sales optioned programs well merck co inc merck march entered license collaboration agreement merck sharp dohme corp subsidiary merck jointly develop commercialize longacting investigational treatments hiv combine gileads investigational capsid inhibitor lenacapavir mercks investigational nucleoside reverse transcriptase translocation inhibitor islatravir collaboration initially focused longacting oral injectable formulations terms agreement gilead merck share global development commercialization costs respectively across oral injectable formulation programs longacting oral products approved gilead would lead commercialization us merck would lead commercialization european union eu rest world longacting injectable products approved merck would lead commercialization us gilead would lead commercialization eu rest world terms agreement gilead merck would jointly promote combination products us certain major markets successful would share global product revenues merck equally product revenues surpass certain pre determined per formulation revenue tiers upon passing billion net product sales oral combination given calendar year share revenue would increase revenues threshold calendar year upon passing billion net product sales injectable combination given calendar year share revenue increase revenues threshold calendar year reimbursements rd costs merck recorded within research development expenses consolidated statements income expenses recognized agreement material years ended december revenues recognized agreement years ended december also option license certain mercks investigational oral integrase inhibitors develop combination lenacapavir reciprocally merck option license certain gileads investigational oral integrase inhibitors develop combination islatravir company may exercise option investigational oral integrase inhibitor company within first five years execution agreement following completion first phase clinical trial integrase inhibitor upon exercise option companies split development costs revenues unless nonexercising company decides opt case nonexercising company paid royalty december merck announced decision parties stop dosing participants phase clinical study evaluating oralweekly combination treatment regimen lenacapavir islatravir following decision fda place clinical holds investigational new drug applications certain formulations islatravir september merck announced study would resume amended protocol lower dose islatravir arcus may entered transaction arcus publicly traded oncologyfocused biopharmaceutical company included entry option license collaboration agreement collaboration agreement common stock purchase agreement investor rights agreement together subsequently amended stock purchase agreements accordance terms collaboration agreement stock purchase agreements closed july made upfront payment million acquired approximately million shares arcus common stock approximately million total million initial cash payments including transactional costs made agreements recorded million equity investment calculated based arcus closing stock price closing date transaction remaining million attributed acquired license option rights million representing iprd assets alternative future use ii million issuance premium equity purchase iii million direct transactional costs amounts expensed acquired inprocess research development expenses year ended december consolidated statements income stock purchase agreements right purchase arcus additional shares maximum outstanding voting stock arcus fiveyear period ending third quarter also subject threeyear standstill ending second quarter restricting certain activity part may separate secondary equity offering acquired million shares common stock arcus approximately million first quarter also acquired approximately million additional shares arcus common stock million result currently total million shares arcus represented approximately issued outstanding voting stock arcus immediately following closing first quarter transaction pursuant collaboration agreement gilead right opt current future clinicalstage product candidates ten years following closing transaction november exercised options three arcus clinical stage programs amended collaboration agreement option exercise amendment transaction closed december triggering collaboration optin payments million waiving million option continuation payment would due arcus third quarter net option charge million included within acquired inprocess research development expenses consolidated statements income year ended december collaboration optin payments million recorded current liabilities consolidated balance sheets december paid arcus january payments arcus included within net cash used investing activities consolidated statements cash flows first quarter amended collaboration agreement companies codevelop share global costs related clinical programs recorded million costs research development expenses consolidated statements income year ended december optioned molecules achieve regulatory approval companies cocommercialize equally share profits us gilead hold exclusive commercialization rights outside us subject rights arcuss existing collaboration partners pay arcus tiered royalties percentage net sales ranging mid teens low twenties collaboration agreement may also pay additional million option fourth sixth eighth anniversaries agreement unless terminated early maintain rights opt future arcus programs duration contact term pionyr june entered transaction pionyr privately held company pursuing novel biology field immunooncology included entry two separate merger agreements one contemplating initial acquisition equity interest pionyr providing us exclusive option subject certain terms conditions acquire remaining outstanding capital stock pionyr together pionyr merger option agreements rd service agreement july closed transaction made cash payments million account investment pionyr using equity method accounting equity interest provides us ability exercise significant influence pionyr investment pionyr consisting transaction price noted transaction costs exceeded prorata portion pionyr 's net assets transaction closing determined resulting basis difference primarily relates pionyrs iprd alternative future use pionyr business defined accounting standards result immediately recorded charge basis difference million acquired inprocess research development expenses consolidated statements income year ended december carrying value equity method investment pionyr zero december estimated fair value exclusive option acquire remaining outstanding capital stock pionyr approximately million based probability weighted option pricing model using unobservable inputs considered level fair value measurement disclosure guidance estimated amount recorded longterm assets consolidated balance sheets may choose exercise exclusive option purchase remaining equity interest pionyrs current shareholders million option exercise fee billion potential future milestone payments upon achievement certain development regulatory milestones option purchase expire following earliest occurrence specified events including delivery data following completion certain phase b trials pionyr rd service agreement made initial cash funding million recorded charge acquired inprocess research development expenses consolidated statements income year ended december addition committed provide additional payments million pionyr upon achievement certain development milestones accrued million milestone payments related initiation two phase studies charge acquired inprocess research development expenses consolidated statements income year ended december payment made first quarter tizona july entered transaction tizona privately held company developing cancer immunotherapies included entry two separate merger agreements one contemplating initial acquisition equity interest tizona providing us exclusive option subject certain terms conditions acquire remaining outstanding capital stock tizona together tizona merger option agreements development agreement august closed transaction tizona made cash payments million tizonas shareholders accordance terms tizona merger option agreements account investment tizona using equity method accounting equity interest provides us ability exercise significant influence tizona investment tizona consisting transaction price noted transaction costs exceeded prorata portion tizonas net assets transaction closing determined resulting basis difference primarily relates tizonas iprd alternative future use tizona business defined accounting standards result year ended december immediately recorded charge basis difference million acquired inprocess research development expenses consolidated statements income carrying value equity method investment tizona zero december estimated fair value exclusive option acquire remaining outstanding capital stock tizona approximately million based probability weighted option pricing model using unobservable inputs considered level fair value measurement disclosure guidance estimated amount recorded longterm assets consolidated balance sheets may choose exercise exclusive option purchase remaining equity interest tizonas current shareholders million option exercise fee billion potential future milestone payments upon achievement certain development regulatory milestones option purchase expire following earliest occurrence specified events including delivery data following completion certain phase b trials tizona development agreement committed provide funding tizona million recorded acquired inprocess research development expenses consolidated statements income year ended december tango therapeutics inc tango august entered transaction tango privately held company pursuing innovative targeted immune evasion therapies patients cancer proprietary crisprenabled functional genomics target discovery platform included entry amended restated research collaboration license agreement stock purchase agreement together tango collaboration stock purchase agreements upon entering transaction made upfront payment million million equity investment tango year ended december recorded million upfront expense acquired inprocess research development expenses consolidated statements income third quarter made additional million equity investment tango became publicly traded company accordingly equity investment since recorded prepaid current assets consolidated balance sheets fair market value tango collaboration stock purchase agreements gilead right option programs sevenyear collaboration million per program optin extension milestone payments products tango opts codevelop copromote parties equally split profits losses well development costs us products tango opt codevelop copromote pay tango low doubledigit tiered royalties net sales provide tango milestone payments royalties sales outside us jounce therapeutics inc jounce september entered transaction jounce publicly traded company developing novel cancer immunotherapies included entry license registration rights stock purchase agreements together jounce license stock purchase agreement october closed transaction made total payment million recorded million upfront expense acquired inprocess research development expenses consolidated statements income million equity investment longterm assets consolidated balance sheets representing approximately issued outstanding voting stock jounce immediately following transaction calculated based jounces closing stock price closing date transaction december amended existing license agreement jounce enabling us buy remaining contingent payments potentially due license agreement million expensed acquired inprocess research development expenses consolidated statements income paid going forward solely responsible research development commercialization immunotherapy specified license agreement galapagos filgotinib collaboration closed license collaboration agreement galapagos clinicalstage biotechnology company based belgium development commercialization filgotinib jakselective inhibitor evaluated inflammatory disease indications filgotinib agreement terms filgotinib agreement amended agreement obtained exclusive worldwide royaltybearing sublicensable license filgotinib products containing filgotinib december gilead galapagos amended agreement allow galapagos assume development manufacturing commercialization certain rights filgotinib europe connection amendments agreement gilead agreed irrevocably pay galapagos million approximately million total amount gilead paid million approximately million january additional million approximately million april million approximately million accrued full amount liability charge research development expenses consolidated statements income year ended december addition galapagos longer eligible receive future milestone payments relating filgotinib europe global collaboration august closed option license collaboration agreement galapagos collaboration agreement subscription agreement galapagos subscription agreement galapagos pursuant parties entered global collaboration covers galapagos current future product portfolio filgotinib pursuant galapagos subscription agreement purchased million new ordinary shares galapagos issued warrants confer right subscribe time time number new shares issued galapagos sufficient bring number shares owned us issued outstanding shares time exercises currently million shares approximately shares issued outstanding time last purchase subject year standstill restricting ability acquire voting securities galapagos exceeding issued outstanding voting securities galapagos agreed without prior consent galapagos dispose equity securities galapagos prior second anniversary closing galapagos subscription agreement dispose equity securities galapagos thereafter fifth anniversary closing galapagos subscription agreement disposal would less thenissued outstanding voting securities galapagos subject certain exceptions termination events april amended galapagos subscription agreement extend initial lockup provision certain galapagos shares august august respect programs galapagos current future pipeline exercise option program pay million option exercise fee per program addition galapagos receive tiered royalties ranging net sales territories galapagos product optioned us exercise option program parties share equally development costs mutually agreed commercialization costs incurred subsequent exercise option may terminate collaboration entirety programbyprogram countrybycountry basis advance notice well following customary termination events two designees appointed galapagos board directors janssen compleraeviplera odefsey entered license collaboration agreement janssen formerly tibotec pharmaceuticals develop commercialize fixeddose combination truvada janssens nonnucleoside reverse transcriptase inhibitor rilpivirine combination approved us eu sold brand name complera us eviplera eu agreement amended expand collaboration include another product containing janssens rilpivirine emtricitabine tenofovir alafenamide odefsey amended agreement janssen granted us exclusive license compleraeviplera odefsey worldwide retained rights distribute combination products certain countries outside us neither party restricted combining drugs drug products except similar components compleraeviplera odefsey responsible manufacturing compleraeviplera odefsey lead role registration distribution commercialization products except countries janssen distributes janssen exercised right codetail combination product countries selling party financial provisions amendment selling party sets price combined products parties share revenues based ratio net selling prices partys components subject certain restrictions adjustments retain specified percentage janssens share revenues including major markets sales products included product sales janssens share revenues included cost goods sold consolidated statements income cost goods sold relating janssens share million million million years ended december respectively termination agreement may product country basis depend circumstances including withdrawal product market material breach either party expiry revenue share payment term may terminate agreement without cause respect countries sell products case janssen right become selling party country product launched market fewer years symtuza amended license collaboration agreement janssen develop commercialize fixeddose combination janssens darunavir cobicistat emtricitabine tenofovir alafenamide gilead compounds combination approved us eu july september respectively sold brand name symtuza terms amendment granted janssen exclusive license symtuza worldwide janssen responsible manufacturing registration distribution commercialization symtuza worldwide responsible intellectual property related gilead compounds exclusive supplier gilead compounds neither party restricted combining drugs drug products except similar components symtuza janssen sets price symtuza parties share revenue based ratio net selling prices partys components subject certain restrictions adjustments intellectual property license supply obligations related gilead compounds accounted single performance obligation license deemed predominant item revenue share relates recognize share symtuza revenue period corresponding sales symtuza janssen occur record share symtuza revenue product sales consolidated statements income primarily supply gilead compounds janssen symtuza termination agreement may product country basis depend circumstances including withdrawal product market material breach either party expiry revenue share payment term janssen may terminate agreement without cause countrybycountry basis case gilead right become selling party countryies product launched market fewer years janssen may also terminate entire agreement without cause japan tobacco inc japan tobacco japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor countries world excluding japan japan tobacco retained rights effective december entered agreement japan tobacco acquire rights market distribute certain products hiv portfolio japan expand rights develop commercialize elvitegravir include japan responsible marketing products january responsible seeking regulatory approval territories required use diligent efforts commercialize elvitegravir treatment hiv infection bear costs expenses associated commercialization efforts pay royalty japan tobacco based product sales sales products included product sales consolidated statements income royalties due japan tobacco included cost goods sold consolidated statements income royalty expenses recognized million million million years ended december respectively terms agreement paid japan tobacco million cash recognized intangible asset million reflecting estimated fair value marketingrelated rights acquired japan tobacco intangible asset amortized nine years representing period majority benefits expected derived applicable products hiv portfolio amortization expense classified selling expense recorded selling general administrative expenses consolidated statements income termination agreement may product country basis depend circumstances including material breach either party expiry royalty payment term may also terminate entire agreement without cause everest april everest immunomedics entered agreement granting everest exclusive license develop commercialize trodelvy greater china south korea singapore indonesia philippines vietnam thailand malaysia mongolia territories gilead subsequently acquired immunomedics october assumed everest license supply agreement provided certain sales milestones royalties payments made gilead recorded million finitelived asset part purchase accounting fourth quarter reacquired development commercialization rights trodelvy everest terminated previous agreement terms new agreement gilead make million upfront termination payments everest million made remaining amounts included current liabilities consolidated balance sheets december addition everest eligible receive million potential additional payments upon achievement certain regulatory commercial milestones accounted new agreement contract termination includes reacquisition commercial rights settlement preexisting relationship everest result recorded expense million selling general administrative expenses consolidated statements income primarily represents upfront costs writeoff remaining value preexisting asset related prior agreement addition recorded acquired finitelived asset fair value million commercial rights reacquired products approved territories collaboration arrangements individually significant entered several collaborations equity investments licensing arrangements well similar arrangements consider individually material recorded upfront collaboration expenses related arrangements million million million years ended december respectively within acquired inprocess research development expenses consolidated statements income debt credit facilities following table summarizes carrying amount borrowings various financing arrangements millions carrying amount type borrowing issue date maturity date interest rate december december senior unsecured september march senior unsecured september september senior unsecured september september senior unsecured september september senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march senior unsecured september october senior unsecured september october senior unsecured september september senior unsecured september september senior unsecured september october senior unsecured december december senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march senior unsecured september october total senior unsecured notes liability related future royalties total debt net less current portion longterm debt obligations net total longterm debt net senior unsecured notes february repaid million senior unsecured notes prior march maturity exercising par call option additionally july repaid billion senior unsecured notes prior september maturity exercising par call option new debt issued senior unsecured fixed rate notes may redeemed option redemption price equal greater principal amount notes redeemed ii sum determined independent investment banker present values remaining scheduled payments principal interest notes redeemed exclusive interest accrued date redemption discounted redemption date semiannual basis treasury rate plus makewhole premium defined terms notes senior unsecured fixed rate notes also par call feature exercisable option redeem notes par whole part dates ranging two six months prior maturity case accrued unpaid interest also required redeemed date redemption billion senior unsecured notes due september also different call feature exercisable option redeem notes par whole part time maturity event change control downgrade rating senior unsecured notes investment grade moodys investors service inc sp global ratings holders may require us purchase portion notes price equal aggregate principal amount notes repurchased plus accrued unpaid interest date repurchase required comply certain covenants note indentures governing senior unsecured notes december violation covenants liability related future royalties connection acquisition immunomedics assumed liability related funding arrangement originally entered immunomedics rpi finance trust rpi prior acquisition immunomedics funding agreement rpi right receive certain royalty amounts subject certain reductions based net sales trodelvy calendar quarter term agreement approximately liability amortized using effective interest rate method resulting recognition interest expense years estimated timing amount future expected royalty payments estimated term reassessed reporting period impact changes estimates recognized liability related interest expense prospectively liability related future royalties primarily included longterm debt net consolidated balance sheets revolving credit facilities june entered new billion fiveyear revolving credit facility maturing june revolving credit facility revolving credit facility used working capital requirements general corporate purposes including without limitation acquisitions december amounts outstanding revolving credit facility revolving credit facility contains customary representations warranties affirmative negative covenants events default december compliance covenants loans revolving credit facility bear interest either term secured overnight financing rate sofr plus applicable percentage ii base rate plus applicable percentage defined revolving credit facility agreement may terminate reduce commitments may prepay loans credit facility whole part time without premium penalty contractual maturities financing obligations following table summarizes aggregate future principal maturities senior unsecured notes december millions amount thereafter total interest expense interest expense debt credit facilities related contractual coupon rates amortization debt discount issuance costs million billion leases operating leases consist primarily properties equipment administrative manufacturing rd activities leases include options extend terms years include options terminate lease within one year lease commencement date december material finance leases operating lease expense including variable costs shortterm leases million million million respectively following table summarizes balance sheet information related operating leases december millions except weighted average amounts classification rightofuse assets net longterm assets lease liabilities current accrued liabilities lease liabilities noncurrent longterm obligations weighted average remaining lease term years years weighted average discount rate following table summarizes supplemental information related operating leases year ended december millions cash paid amounts included measurement lease liabilities rightofuse assets obtained exchange lease liabilities following table summarizes maturity analysis operating lease liabilities showing aggregate lease payments december millions amount thereafter total undiscounted lease payments less imputed interest total discounted lease payments commitments contingencies legal proceedings party various legal actions certain significant matters described recognize accruals actions extent conclude loss probable reasonably estimable accrue best estimate loss within range however estimate range better accrue minimum amount range determine material loss reasonably possible loss range loss estimated disclose possible loss unless otherwise noted outcome matters either expected material possible determine reasonably estimate maximum potential exposure range possible loss material accruals matters described december december recorded accrual billion accrued current liabilities consolidated balance sheets previously disclosed legal settlement related bictegravir litigation paid february litigation related sofosbuvir acquired pharmasset inc acquisition acquired sofosbuvir nucleotide analog acts inhibit replication hcv received approval fda sofosbuvir sold brand name sovaldi sofosbuvir also included marketed hcv products received number litigation claims regarding sofosbuvir carefully considered claims prior following acquisition believe without merit predict ultimate outcome claims range loss aware patents patent applications owned third parties may future alleged parties cover use hcv products third parties obtain valid enforceable patents successfully prove infringement patents hcv products could required pay significant monetary damages predict ultimate outcome intellectual property claims related hcv products spent continue spend significant resources defending claims litigation university minnesota university minnesota university obtained us patent patent purports broadly cover nucleosides antiviral anticancer activity university filed lawsuit us us district court district minnesota alleging commercialization sofosbuvircontaining products infringes patent believe patent invalid infringed continued commercialization sofosbuvir court granted motion transfer case california also filed petitions inter partes review us patent trademark office patent trial appeal board ptab alleging asserted claims invalid anticipation obviousness ptab instituted one petitions merits hearing held february us district court northern district california stayed litigation ptab concluded inter partes review initiated may ptab issued written decision finding asserted claims universitys patent invalid july university appealed decision oral arguments court appeals federal circuit held january litigation us district court remain stayed appeal proceedings litigation nucana plc nucana nucana obtained european patent ep patent allegedly covers sofosbuvir opposition proceedings european patent office epo held february epo opposition division upheld validity ep patent amended form epo scheduled appeal hearing march continue believe amended ep patent claims invalid subsequent epo opposition decision initiated proceedings invalidate uk counterparts ep patent related patent european patent ep patent high court england wales nucana also filed counterclaims us high court england wales alleging patent infringement uk counterparts seeking damages relief uk case heard january early february april nucana also filed lawsuit us germany landgericht dsseldorf alleging patent infringement german counterpart ep patent seeking damages injunctive relief april filed action grant compulsory license federal patent court germany july dsseldorf court determined nucanas german counterpart ep patent infringed granted injunction august gilead filed notice appeal regarding dsseldorf courts decision hearing scheduled august litigation related axicabtagene ciloleucel october juno therapeutics inc sloan kettering cancer center collectively juno filed lawsuit us us district court central district california alleging commercialization axicabtagene ciloleucel sold commercially yescarta infringes us patent patent jury trial held patent december jury found asserted claims patent valid willfully infringed asserted claims patent jury also awarded juno damages amounts million upfront payment running royalty october date jurys verdict parties filed posttrial motions first quarter trial judge entered judgment april trial judge affirmed jurys verdict enhanced past damages maintained royalties future yescarta sales april filed appeal seeking reverse judgment obtain new trial due errors made trial judge july appeals court heard oral arguments august court appeals federal circuit cafc reversed jury verdict finding asserted claims junos patent invalid october juno filed petition rehearing cafc january cafc denied junos petition rehearing june juno filed petition certiorari seeking review supreme court supreme court rejected junos petition january making cafc judgment final litigation relating preexposure prophylaxis august filed petitions requesting inter partes review us patent nos collectively hhs patents ptab hhs patents assigned us department health human services hhs purport claim process protecting primate host infection immunodeficiency retrovirus administering combination ftc tenofovir disoproxil fumarate tdf taf prior exposure host immunodeficiency retrovirus process commonly known preexposure prophylaxis prep november us department justice filed lawsuit us us district court delaware alleging sale truvada descovy use prep infringes hhs patents february ptab declined institute petitions inter partes review hhs patents april filed breach contract lawsuit us federal government us court federal claims alleging violations three material transfer agreements mtas related research underlying hhs patents two clinical trial agreements ctas us centers disease control prevention related prep research although predict certainty ultimate outcome litigation matters believe us federal government breached mtas cta truvada descovy infringe hhs patents hhs patents invalid prior art descriptions truvadas use prep postexposure prophylaxis well physicians patients using claimed methods years hhs filed applications patents trial bifurcated portion lawsuit court federal claims held june november court determined government breached three mtas court also made findings fact relating ctas declined issue decision breach ctas trial delaware district court trial date lawsuit delaware district court set may separate trial court federal claims determine damages gilead owed based governments breach yet set litigation generic manufacturers part approval process products fda granted us new chemical entity nce exclusivity period manufacturers applications approval generic versions products approved generic manufacturers may challenge patents protecting products granted nce exclusivity one year prior end nce exclusivity period generic manufacturers sought may continue seek fda approval similar identical drug abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug sale generic versions products prior patent expiration would significant negative effect revenues results operations seek approval generic version product nce status generic company may submit anda fda four years branded products approval october received letter lupin ltd lupin indicating submitted anda fda requesting permission market manufacture generic version symtuza product commercialized janssen gilead shares revenues november along janssen products lp janssen janssen filed patent infringement lawsuit lupin coplaintiffs us district court delaware separately filed additional lawsuit lupin asserting infringement two additional patents court second case stayed trial scheduled october september received letter apotex inc apotex corp apotex stating submitted anda generic version symtuza october along janssen filed patent infringement lawsuit apotex coplaintiffs us district court delaware separately filed additional lawsuit apotex asserting infringement two additional patents court starting march received letters lupin laurus labs laurus cipla ltd cipla indicating submitted andas fda requesting permission market manufacture generic versions biktarvy lupin laurus cipla challenged validity three five patents listed orange book associated biktarvy filed lawsuit lupin laurus cipla may us district court delaware intend enforce defend intellectual property trial scheduled december european patent claims several parties filed oppositions epo requesting revocation one granted european patents covering sofosbuvir expires epo upheld validity certain claims sofosbuvir patent appealed decision seeking restore original claims several original opposing parties also appealed requesting full revocation appeal hearing held november final decision regarding validity claims yet announced several parties filed oppositions epo requesting revocation granted european patent relating sofosbuvir expires epo conducted oral hearing opposition upheld claims original opposing parties appealed requesting full revocation hearing appeal scheduled september several parties filed oppositions epo requesting revocation granted european patent relating taf hemifumarate expires epo upheld validity claims taf hemifumarate patent three parties appealed decision hearing appeal scheduled march appeal process may take several years epo opposition proceedings confident strength patents predict ultimate outcome oppositions unsuccessful defending oppositions patent claims may narrowed revoked patent protection sofosbuvir taf hemifumarate eu could substantially shortened eliminated entirely patents revoked european patents granted covering compounds exclusivity may based entirely regulatory exclusivity granted ema lose patent protection compounds revenues results operations could negatively impacted years including succeeding year exclusivity lost antitrust consumer protection along bristolmyers squibb company bms johnson johnson inc named defendants class action lawsuits filed related various drugs used treat hiv including drugs used combination antiretroviral therapy plaintiffs allege defendants engaged various conduct restrain competition violation federal state antitrust laws state consumer protection laws lawsuits consolidated pending us district court northern district california lawsuits seek bring claims behalf direct purchasers consisting largely wholesalers indirect endpayor purchasers including health insurers individual patients plaintiffs seek damages permanent injunctive relief relief second half first half several plaintiffs filed separate lawsuits effectively opting class action cases asserting claims substantively putative classes cases coordinated class actions trial set may january along bms janssen products lp named defendants lawsuit filed superior court state california county san mateo aetna inc behalf affiliates subsidiaries effectively opts aetna plaintiffs class actions allegations substantively class actions aetna plaintiffs seek damages permanent injunctive relief relief september along generic manufacturers cipla cipla usa inc together cipla defendants named defendants class action lawsuit filed us district court northern district california jacksonville police officers fire fighters health insurance trust jacksonville trust behalf endpayor purchasers jacksonville trust claims settlement agreement us cipla defendants settled patent dispute relating patents covering emtriva truvada atripla products permitted generic entry prior patent expiry violates certain federal state antitrust consumer protection laws plaintiff seeks damages permanent injunctive relief relief february along bms teva pharmaceutical industries ltd named defendants lawsuit filed first judicial district court state new mexico county santa fe new mexico attorney general new mexico attorney general alleges defendants restrained competition violation new mexico antitrust consumer protection laws new mexico attorney general seeks damages permanent injunctive relief relief believe cases without merit predict ultimate outcome plaintiffs successful claims could required pay significant monetary damages could subject permanent injunctive relief awarded favor plaintiffs product liability named defendant one class action lawsuit various product liability lawsuits related viread truvada atripla complera stribild plaintiffs allege viread truvada atripla complera andor stribild caused experience kidney bone andor tooth injuries lawsuits pending state federal court california delaware florida missouri new york involve plaintiffs plaintiffs cases seek damages relief various grounds alleged personal injury economic loss first bellwether trial california state court scheduled begin october currently stayed california first district court appeal considers merits plaintiffs theories liability first bellwether trial california federal court scheduled begin january intend vigorously defend actions believe cases without merit predict ultimate outcome plaintiffs successful claims could required pay significant monetary damages government investigation received subpoena us attorneys office southern district new york requesting documents related promotional speaker programs hiv cooperating inquiry qui tam litigation former sales employee filed qui tam lawsuit gilead march us district court eastern district pennsylvania following governments decision intervene suit case unsealed december lawsuit alleges certain gileads hcv sales marketing activities violated federal false claims act various state false claims acts relator seeks available relief statutes health choice advocates llc health choice filed qui tam lawsuit gilead april new jersey state court following new jersey attorney generals offices decision intervene suit health choice served us original complaint august lawsuit alleges gilead violated new jersey false claims act clinical educator programs sovaldi harvoni hcv hiv patient access programs lawsuit seeks available relief new jersey false claims act april trial court granted motion dismiss prejudice health choice appealed trial courts dismissal health choice filed another qui tam lawsuit gilead may making similar allegations texas state court following texas attorney generals offices decision intervene suit health choice served us original complaint october lawsuit alleges gilead violated texas medicare fraud prevention act tmfpa clinical educator programs sovaldi harvoni hcv hiv patient access programs lawsuit seeks available relief tmfpa september texas court appeals sixth court appeals district granted request stay texas litigation pending final judgment eastern district pennsylvania lawsuit filed march discussed intend vigorously defend actions believe cases without merit predict ultimate outcomes plaintiffs successful claims could required pay significant monetary damages securities litigation immunomedics several former officers directors named defendants putative class actions filed consolidated september plaintiffs filed consolidated complaint november amended complaint july plaintiffs allege immunomedics individual defendants violated federal securities laws connection immunomedics biologics license application trodelvy seek certification class shareholders damages relief consolidated lawsuit pending us district court district new jersey june plaintiffs filed motion class certification immunomedics submitted opposition july parties agreed settle litigation motion seeking preliminary approval settlement granted february court yet entered final order approving settlement matters party various legal actions arose ordinary course business believe legal actions material adverse impact consolidated financial position results operations cash flows stockholders equity stock repurchase programs first quarter board directors authorized billion stock repurchase program program purchases program may made open market privately negotiated transactions billion stock repurchase program authorized board directors first quarter completed fourth quarter started repurchases program december december remaining authorized repurchase amount program billion following table summarizes stock repurchases open market transactions programs year ended december millions except per share amounts shares repurchased retired amount average price per share addition repurchases stock repurchase programs repurchased shares common stock withheld us employee restricted stock awards satisfy applicable tax withholding obligations shares excluded table use par value method accounting stock repurchases par value method common stock first charged par value shares involved excess cost shares acquired par value allocated additional paidin capital based estimated average sales price per issued share excess amounts charged retained earnings dividends following table summarizes cash dividends declared common stock millions except per share amounts dividend per share amount dividend per share amount first quarter second quarter third quarter fourth quarter total rsus psus dividend equivalent rights entitling holders dividend equivalents paid upon vesting share underlying unit february announced board directors declared quarterly cash dividend increase per share common stock payment date march stockholders record close business march future dividends subject declaration board directors preferred stock million shares authorized preferred stock issuable series board authorized determine designation powers preferences rights series preferred stock outstanding december accumulated comprehensive income following table summarizes changes accumulated comprehensive income component net tax unrealized gains unrealized gains losses available losses cash foreign currency forsale debt flow hedges net millions translation securities net tax tax total balance december net unrealized gain loss reclassifications net income net current period comprehensive income loss balance december net unrealized gain loss reclassifications net income net current period comprehensive income loss balance december net unrealized gain loss reclassifications net income net current period comprehensive income loss balance december employee benefits stockbased compensation equity incentive plans summary may stockholders approved adopted gilead sciences inc equity incentive plan amended plan part acquisition forty seven assumed forty seven inc equity incentive plan subsequently amended restated gilead sciences inc equity incentive plan amended restated plan part immunomedics acquisition assumed immunomedics amended restated longterm incentive plan subsequently merged plan may stockholders approved adopted gilead sciences inc equity incentive plan plan plan authorized issuance total million shares common stock awards may granted plan plan since approval plan broadbased incentive plans provide grant equitybased awards including rsus psus stock options restricted stock performance awards employees directors consultants december total million shares remain available future grant plan rsus grant timebased rsus certain employees part annual employee equity compensation review program well new hire employees nonemployee members board rsus sharebased awards entitle holder receive freely tradable shares common stock upon vesting rsus generally vest three four years date grant psus grant psus vest upon achievement specified market performance goals could include achieving total shareholder return compared predetermined peer group achieving revenue targets actual number common shares ultimately issued calculated multiplying number psus payout percentage ranging awards generally vest committee subcommittee board determined specified market performance goals achieved stock options option grants designated either nonstatutory incentive stock options exercise price stock options may less fair market value common stock grant date stock option may term excess years employee stock options generally vest three four years stock options may settled cash shares common stock including net issuance using shares otherwise purchasable option pay exercise price espp summary espp employees purchase shares common stock based percentage compensation subject certain limits purchase price per share equal lower fair market value common stock offering date purchase date espp offers sixmonth look back feature espp purchases settled common stock espps previously authorized available pool shares total million shares common stock authorized issuance espp million shares available issuance espp december stockbased compensation expense following tables summarize total stockbased compensation expense included consolidated statements income broken award type expense type year ended december millions rsus psus stock options espp acquisitionrelated expense stockbased compensation expense included total costs expenses accelerated postacquisition stockbased compensation expense million related mirobio acquisition million million related acquisitions immunomedics forty seven respectively year ended december millions cost goods sold research development expenses selling general administrative expenses stockbased compensation expense included total costs expenses income tax effect stockbased compensation expense net tax rsus following tables summarize rsu activity rsus weighted average grant date fair millions except per share amounts shares value per share outstanding december granted vested forfeited outstanding december year ended december millions except per share amounts weightedaverage grant date fair value rsus granted total fair value rsus respective vesting dates december million unrecognized compensation cost related unvested rsus expected recognized weightedaverage period years psus following tables summarize psu activity psus weighted average grant date fair millions except per share amounts shares value per share outstanding december granted vested forfeited outstanding december year ended december millions except per share amounts weightedaverage grant date fair value psus granted total fair value psus respective vesting dates december million unrecognized compensation cost related unvested psus expected recognized weightedaverage period years stock options following tables summarize activity information related stock options weighted weightedaverage aggregate average remaining intrinsic shares exercise price contractual term value millions dollars years millions outstanding december granted forfeited expired exercised outstanding december exercisable december expected vest net estimated forfeitures december aggregate intrinsic value represents value closing stock price last trading day year excess weightedaverage exercise price multiplied number options outstanding exercisable year ended december millions except per share amounts weightedaverage grant date fair value stock options granted total intrinsic value options exercised used following weightedaverage assumptions blackscholes model calculate estimated fair value stock option awards year ended december millions expected volatility expected terms years riskfree interest rate expected dividend yield december million unrecognized compensation cost related stock options expected recognized estimated weightedaverage period years espp following table summarizes espp activity year ended december millions except per share amounts shares issued amount paid employees shares weightedaverage grant date fair value espp shares granted total fair value espp shares respective vesting dates used following weightedaverage assumptions blackscholes model calculate estimated fair value espp awards year ended december expected volatility expected terms years riskfree interest rate expected dividend yield deferred compensation maintain retirement saving plan eligible us employees may defer compensation income tax purposes section k internal revenue code gilead sciences k plan certain foreign subsidiaries maintain defined benefit plans required local regulatory requirements total matching contribution expense gilead sciences k plan defined benefit plans million million million respectively maintain deferred compensation plan directors key employees may defer compensation amounts deferred participants deposited rabbi trust total assets liabilities associated deferred compensation plan million million december respectively earnings per share following table shows calculation basic diluted earnings per share attributable gilead year ended december millions except per share amounts net income attributable gilead shares used basic earnings per share attributable gilead calculation dilutive effect stock options equivalents shares used diluted earnings per share attributable gilead calculation basic earnings per share attributable gilead diluted earnings per share attributable gilead potential shares common stock excluded computation diluted earnings per share attributable gilead effect would antidilutive million million million respectively income taxes income income taxes consists following year ended december millions domestic foreign income income taxes income tax expense consists following year ended december millions federal current deferred state current deferred foreign current deferred income tax expense reconciliation federal statutory tax rate applied income income taxes effective tax rate summarized follows year ended december federal statutory rate state taxes net federal benefit foreign earnings different rates research credits us tax foreign earnings foreignderived intangible income deduction settlement tax examinations acquired iprd related charges changes valuation allowance nontaxable unrealized loss investment effective tax rate significant components deferred tax assets liabilities follows december millions deferred tax assets net operating loss carryforwards stockbased compensation reserves accruals currently deductible excess tax basis book basis intangible assets upfront milestone payments research credit carryforwards equity investments liability related sale future royalties capitalized rd expenditures net total deferred tax assets valuation allowance valuation allowance total deferred tax assets deferred tax liabilities property plant equipment excess book basis tax basis intangible assets total deferred tax liabilities net deferred tax assets liabilities valuation allowance increased million december million december primarily due unrealized losses equity investments subject full valuation allowance increased million december million december primarily due california research development tax credits december us federal net operating loss tax credit carryforwards approximately million million respectively start expire utilized addition state net operating loss tax credit carryforwards approximately billion million respectively start expire respectively utilized utilization net operating losses tax credits may subject annual limitation due ownership change limitations provided internal revenue code amended similar state provisions annual limitation may result expiration net operating losses credits utilization file federal state foreign income tax returns us many foreign jurisdictions federal income tax purposes statute limitations open onwards onwards california income tax purposes certain acquired entities statute limitations open years inception due utilization net operating losses credits carried prior years income tax returns subject audit federal state foreign tax authorities currently examination internal revenue service irish tax authorities tax years differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions total unrecognized tax benefits million million december respectively recognized would reduce effective tax rate period recognition interest penalties related unrecognized tax benefits included income tax benefit million income tax expense million income tax benefit million consolidated statements income years ended december respectively accrued interest penalties related unrecognized tax benefits million million december respectively december believe reasonably possible unrecognized tax benefits significantly change next months following rollforward total gross unrecognized tax benefits year ended december millions beginning balance tax positions related current year additions reductions tax positions related prior years additions reductions settlements lapse statute limitations ending balance connection tax cuts jobs act recorded federal income tax payable transition tax mandatory deemed repatriation foreign earnings payable eightyear period federal income tax payable transition tax billion billion december respectively following table summarizes anticipated timing payments associated transition tax december millions amount total subsequent events arcellx january closed agreement enter global strategic collaboration arcellx inc arcellx codevelop cocommercialize arcellxs lead latestage product candidate cartddbcma treatment patients relapsed refractory multiple myeloma terms agreement arcellx receive upfront cash payment million million equity investment well potential contingent payments companies share development clinical trial commercialization costs cartddbcma jointly commercialize product split us profits outside us commercialize product arcellx receive royalties sales tmunity february closed agreement acquire tmunity therapeutics tmunity clinicalstage private biotech company focused nextgeneration car ttherapies technologies terms agreement acquired outstanding shares tmunity already owned gilead approximately million cash consideration item changes disagreements accountants accounting financial disclosure applicable report independent registered public accounting firm stockholders board directors gilead sciences inc opinion internal control financial reporting audited gilead sciences incs internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework coso criteria opinion gilead sciences inc company maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states pcaob consolidated balance sheets company december related consolidated statements income comprehensive income stockholders equity cash flows three years period ended december related notes report dated february expressed unqualified opinion thereon basis opinion companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audit accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate ernst young llp san jose california february item controls procedures evaluation disclosure controls procedures evaluation december carried supervision participation management including chief executive officer chief financial officer effectiveness disclosure controls procedures defined rule ae de securities exchange act amended exchange act controls procedures company designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified securities exchange commissions rules forms information accumulated communicated companys management including chief executive officer chief financial officer appropriate allow timely decisions regarding required disclosure based upon evaluation chief executive officer chief financial officer concluded disclosure controls procedures effective december b managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af df exchange act internal control system designed provide reasonable assurance regarding preparation fair presentation financial statements external purposes accordance generally accepted accounting principles internal control systems matter well designed inherent limitations provide reasonable assurance objectives internal control system met supervision participation management including chief executive officer chief financial officer conducted evaluation effectiveness internal control financial reporting based criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework based evaluation concluded internal control financial reporting effective december independent registered public accounting firm ernst young llp audited consolidated financial statements included item annual report issued report internal control financial reporting december report audit internal control financial reporting appears c changes internal control financial reporting management including chief executive officer chief financial officer evaluated changes internal control financial reporting occurred quarter ended december concluded change quarter materially affected reasonably likely materially affect internal control financial reporting item b information applicable item c disclosure regarding foreign jurisdictions prevent inspections applicable part iii item directors executive officers corporate governance information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed securities exchange commission pursuant regulation connection annual meeting stockholders proxy statement headings gilead board directors nominees board structure executive officers applicable delinquent section reports written code ethics applies directors employees including executive officers including without limitation principal executive officer principal financial officer principal accounting officer controller persons performing similar functions code ethics available website wwwgileadcom investors section governance governance documents intend disclose future amendments certain provisions code ethics waivers code ethics granted executive officers directors website within four business days following date amendment waiver item executive compensation information required item incorporated reference sections proxy statement headings executive compensation committees board directors compensation talent committee report compensation nonemployee board members item security ownership certain beneficial owners management related stockholder matters information required item incorporated reference item annual report heading securities authorized issuance equity compensation plans section proxy statement heading security ownership certain beneficial owners management item certain relationships related transactions director independence information required item incorporated reference sections proxy statement headings gilead board directors board processes item principal accountant fees services information required item incorporated reference section proxy statement heading principal accountant fees services part iv item